Contents

Foreword 2
Panel reflections on the independent review recommendations 5
Executive summary 7
1. Panel overview and approach 21
2. Concepts of race and ethnicity 24
3. What does ‘striving for equity in medical devices’ mean? 28
4. How do unfair biases in medical devices come about? 34
5. Focusing the equity lens 41
6. Potential ethnic and other unfair biases in optical medical devices 45
7. Preventing bias in AI-enabled medical devices 62
8. Future proofing: polygenic risk scores 81
9. Horizon scanning and next steps 91
Appendix A: terms of reference for the Independent Panel 95
Appendix B: panel members’ biographies 97
Appendix C: engagement activities and acknowledgements 101
Appendix D: call for evidence 110
References 115
Foreword

The initial stimulus for this review was growing concern about a specific medical device – the pulse oximeter, which estimates the level of oxygen in the blood – in common use throughout the NHS. The COVID-19 pandemic highlighted that the pulse oximeter may not be as accurate for patients with darker skin tone than for those with lighter skin. An inaccurate reading could potentially lead to harm if there was a delay in identifying dangerously low oxygen levels in patients with darker skin tone, which normally would have triggered referral for more intensive care.

When the Rt Hon Sajid Javid MP, the then Secretary of State for Health and Social Care, asked me to carry out this independent review, the scope was extended to recognise the potential for bias in other medical devices, not just pulse oximeters, and beyond racial and ethnic bias to further unfair biases in performance, including by sex and socio-economic status.

My first step was to invite four wise professionals with a special commitment to equity in healthcare to join me: Professors Raghib Ali, Enitan Carrol, Chris Holmes and Frank Kee. Together, we formed the review panel and made the many decisions about the conduct of the review. This report reflects the conclusions of the whole panel. We were ably supported throughout by a dedicated secretariat of Aleksandra Herbec, Maya Grimes and Jessica Scott.

To understand the latest evidence, we liaised with academics and reviewed relevant research, commissioning a series of focused literature reviews where necessary. To learn from experience in developing or using medical devices, we engaged with a wide range of stakeholders, holding individual and group sessions with patient and public representatives, national leaders from NHS agencies and health professions, medical device regulators, developers and manufacturers, and independent health policy foundations. We also held a public call for evidence. Finally, we tested out our understanding in roundtables and follow-up events. We are immensely grateful to all who offered their advice and wisdom so generously.

In our review, we considered the evidence for differential performance of medical devices by socio-demographic groups that had the potential to lead to poorer healthcare for the population group disadvantaged by the bias. Crucially, we looked for evidence of the causes of the bias to inform our subsequent recommendations.

First, we focused on what we termed ‘optical devices’, where the initial differential performance stems from the physics of the hardware itself. These optical devices – pulse oximeters among them – send light waves of various frequencies through the patient’s skin to make measurements of underlying physiology, but the light reacts differently with varying levels of melanin in the skin.
This differential performance by skin tone would not necessarily be a problem for healthcare if the variation in performance had been recognised and appropriate adjustments made to calibrate the devices according to skin tone. However, no such recognition appears to have happened either in the case of pulse oximeters and in an unknown number of other optical devices, which are not adjusted for differential performance by skin tone. The problem has been compounded in pulse oximeters by the practice of testing the devices on participants with light skin tone, so that these readings are taken as the norm.

There is some evidence – so far only from the US healthcare system and not the NHS – of adverse clinical impact of this racial bias in pulse oximeters on the healthcare received by Black patients compared with White patients. Our recommendations for optical devices, therefore, start with mitigating actions in relation to the pulse oximeters already in widespread use across the NHS and in homes all around the country.

We appreciate that pulse oximeters are valuable clinical tools, so we would definitely not advise curtailment of their use in patients with darker skin tones. Rather, we recommend immediate modifications to existing practice, including guidance for patients, health professionals, manufacturers and other relevant agencies. We commend the current intensive efforts by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, the Food and Drug Administration (FDA) in the US, and the EU to tighten the regulations and guidance on pulse oximeters in response to the evidence of inequities in health outcomes.

For optical devices overall, our recommendations aim at preventing adverse impacts arising in new devices by adding an equity lens to the whole device lifecycle.

Second, we turned our attention to medical devices enabled by artificial intelligence (AI). The advance of AI brings with it not only great potential benefits to society but also possible harm through inherent bias against certain groups in the population, notably women, ethnic minorities and disadvantaged socio-economic groups.

Few outside the health system may appreciate the extent to which AI has become incorporated into every aspect of healthcare, from prevention and screening to diagnostics and clinical decision-making, such as when to increase intensity of care. Our review reveals how existing biases and discrimination in society can unwittingly be incorporated at every stage of the lifecycle of the devices and then magnified in algorithm development and machine learning.

The evidence for adverse clinical impacts of these biases is currently patchy, though indicative. Seven of our recommendations are therefore focused on actions to enable the development of bias-free AI devices, with the voices of the public and patients incorporated throughout.

We were impressed with the initiatives on equity and AI that are underway by the MHRA and other international collaborations. Our recommendations are intended to strengthen and reinforce these ongoing efforts. In the final recommendation on AI, however, action at the highest levels is urgently needed to anticipate potential harm.
We call for a government-appointed taskforce on large language models (LLM) – exemplified by ChatGPT – to assess the health equity impact of these potentially alarming digital technologies, together with the proper resourcing of the regulators to take on the challenges of assessment.

Third, we reviewed an emerging use of genomics – polygenic risk scores (PRS) – to consider what would be needed to future-proof their development in ways that would address equity concerns as they evolved.

The data sources on which PRS draw have a well-established bias against groups with non-European genetic ancestry, but, in addition, we were concerned by the potential for misinterpretation of results by the public and health professionals alike, especially in relation to genetic determinism, which may carry wider societal risks. We were impressed by the intensive efforts already underway nationally to tackle the genetic ancestry bias in major datasets. Our three recommendations, therefore, concentrate on action on the broader societal front.

Last, we identify emerging issues looming on the horizon that now need urgent attention. Our final call to action for future work is a review to be carried out of medical devices encountered during pregnancy and the neonatal period, as part of the wider investigations of health outcomes for ethnic minority and poorer women and their babies.

The panel and I believe wholeheartedly that these recommendations need to be implemented as a matter of priority with full government support. The government is already signalling the need for urgent action on AI regulation by calling the Global Summit on AI Safety in November 2023. But nowhere is the need to ensure AI safety and equity more pressing than in medical care, where built-in biases in applications have the potential to harm already disadvantaged patients. Now is the time to seize the opportunity to incorporate action on equity in medical devices into the overarching global strategies on AI safety.

Professor Dame Margaret Whitehead
Chair – Equity in Medical Devices: Independent Review
Panel reflections on the independent review recommendations

Over the 15-month period that the Independent Review panel convened, reviewed evidence, and spoke to stakeholders, we made a number of reflections which may not be adequately conveyed in the body of the formal report.

The first is on the nature of the bias we found. We found evidence of unfair bias in relation to medical devices, but from what we could discern it was largely unintentional (for example related to the physical properties of optical devices on darker skin tones or unrepresentative datasets in AI algorithms), compounded by testing and evaluation in predominantly White populations. Some of the biases we found were even well-intentioned but misguided, such as the application of race correction factors based on erroneous assumptions of racial or ethnic differences, or attempts to devise ‘fairness metrics’ for AI devices that aim for equality rather than equity. This ‘unintentionality’ and the fact that many of the participants at our expert roundtables focused on or saw only part of the problem, speaks to us about the need for a whole systems or ecosystem view. Differentials in socio-economic conditions (including power, exposure to health hazards, employment, and access to healthcare) together with systemic structural issues, amplify the bias further.

The second reflection is that our review, inevitably and rightly, mainly focused on the potential for ethnic and racial inequities, as these are more obviously likely to arise in the medical devices we covered, but ultimately the biggest driver of health inequity in the UK by far is socio-economic disadvantage (regardless of ethnic group).

Device manufacturers, regulatory bodies and the Department of Health and Social Care (DHSC) should always keep in mind their socio-economic responsibilities,¹ to reduce the inequalities of outcome which result from socio-economic disadvantage and ensure that new medical devices do not exacerbate these already wide inequities.

The third reflection is that the exponential increase in AI-driven applications in medical devices has far surpassed any increase in regulation of AI used to support clinical decision making and AI-derived predictive analytics, including in genomics. There is a real danger that innovations in medical device technology, whether in optical devices, AI or genomics, will not only outstrip the growth in our health professionals’ AI literacy and skills but will also exacerbate inequity, with potential to change the foundations of the doctor–patient relationship in unpredictable ways.
A government-appointed expert panel is required to oversee the inevitable disruption and potential unintended consequences that will arise from the AI revolution in healthcare. This is our final recommendation in the chapter on AI as a medical device.

The fourth reflection is the subject of inequities in access to medical devices, which was out of scope for our review, but is a pressing issue for future action. The poorer access for more disadvantaged socio-economic groups to the new generation of AI and genomic innovations is yet another injustice that should not be tolerated in the NHS. Inequities in access to medical devices form only one part of the wider problem of inequitable access to the health services that people need, which is largely due to structural biases in the broader health ecosystem. Addressing inequities in access is therefore an essential task for the government and leadership of the NHS.

Finally, for our recommendations to be impactful, a renewed sense of urgency and commitment to address inequity is required at the highest levels of government. Additional resources are also required for the MHRA and approved bodies for medical devices to ensure that equity assessments are conducted as part of the approvals process for new medical devices, and in post-marketing surveillance.

It has been a genuine privilege and honour to work on this independent review, and we hope that the implementation of our recommendations will go some way to turning the tide on inequity and unfair biases in medical devices in the NHS.

Margaret Whitehead
Raghib Ali
Enitan Carrol
Chris Holmes
Frank Kee
Executive summary

Scope

A core responsibility of the National Health Service (NHS) is to maintain the highest standards of safety and effectiveness of medical devices currently available for all patients within its care. Evidence has emerged, however, about the potential for racial and ethnic bias in the performance of some medical devices commonly used in the NHS, and that some ethnic groups may receive suboptimal treatment as a result. Beyond racial and ethnic bias, there may be further unfair biases in performance, including by sex and socio-economic status.

This Independent Review was tasked by the Secretary of State for Health and Social Care with establishing the extent and impact of potential racial, ethnic and other factors leading to unfair biases in the design and use of medical devices and to make recommendations for improvements.

Our recommendations were derived from a review of the scientific evidence and extensive engagement activities with both the developers and regulators of medical devices on the one hand, and users and evaluators of the devices in the NHS on the other, including the ultimate users: patients and the public.

Concepts of race and ethnicity in this report

The terms ‘race’ and ‘ethnicity’ are often used interchangeably in the literature. We use the terms ‘racial and ethnic inequities’ and ‘racial and ethnic bias’ to describe concepts where medical devices do not work as well for some ethnic groups as a result of differences in biological characteristics, genetic predisposition, or under-representation in research. In the context of polygenic risk scores (one of the categories of device that we reviewed), we use the term ‘genetic ancestry’ to describe the people that an individual is biologically descended from, including their genetic relationships. Knowledge of a person’s ancestry can help determine frequencies of genetic risk variants, which may vary with ancestry. We briefly explain the relationship between ethnicity and socio-economic status, as deprivation is a major risk factor for most health outcomes, and should also be taken into consideration when making comparisons between ethnic groups.
Applying equity principles to medical devices

There are many equity elements built into the NHS that combine to make it fair and equitable. Considering the relevant elements as equity principles in the context of this review, medical devices approved for use in the NHS should:

- be available to everyone in proportion to need
- support the selection of patients for treatment based on need and risk
- function to the same high standard and quality for all relevant population groups. If there are unavoidable differences in performance in relation to some groups, these need to be understood and mitigated, such as in how the device is calibrated.

We reviewed the evidence on violations of these equity principles, in particular evidence of the application of medical devices leading to biased selection of patients for treatment or differential performance that has the potential to lead to adverse clinical impacts on the health or healthcare of the patients concerned.

This review focused on three types of medical device that may be particularly prone to racial, ethnic or other unfair biases: optical medical devices; artificial intelligence (AI)-enabled medical devices; and polygenic risk scores (PRS) in genomics.

What we found

Optical medical devices

Section 6 on optical devices focuses primarily on pulse oximeters, but also includes other optical medical devices which take measurements through a patient's skin, and where results may vary by skin tone.

There is extensive evidence of poorer performance of pulse oximeters for patients with darker skin tones. Pulse oximeters overestimate true oxygen levels in people with darker skin tones, which is exacerbated in patients with low levels of oxygen saturation. Evidence of harm stemming from this poorer performance has been found in the US healthcare system, where racial and ethnic bias in the performance of the pulse oximeters has been linked to delayed recognition of disease, denied or delayed treatment, worse organ function and death in Black compared with White patients. In these studies, the relationship between oxygenation overestimation and outcome cannot be said to be causative, but points to a strong association. We did not find any evidence from studies in the NHS of this differential performance affecting care but the potential for harm is clearly present.

Recommendations 1 to 3 are therefore focused specifically on pulse oximeters, and cover immediate mitigation measures to ensure existing pulse oximeters can perform to a high standard for all patient groups to avoid serious inequities in health outcomes; improvements in international standards for approval of new pulse oximeter models and the development, ultimately, of smarter devices for measuring blood oxygen saturation that are equally effective across a wide range of skin tones.
We also reviewed evidence for other optical devices where there were scientifically plausible mechanisms for results varying by skin tone. These include near-infrared spectroscopy (NIRS), transcutaneous bilirubinometers and dermoscopes. Evidence is mixed but is suggestive of a degree of bias in such optical devices. For example, underestimation of tissue oxygenation was found in NIRS readings for participants with darker skin tones, with potentially unnecessary treatment given to patients to improve the oxygen values derived from the spectroscopy, when brain oxygenation is normal. Overestimation of total serum bilirubin was found when transcutaneous bilirubinometers were used on infants with darker skin tone, which could lead to needless follow-up blood tests on newborn babies, which are invasive, prolong hospital visits, increase parental stress and interrupt mother-infant bonding. Some dermoscopes used to diagnose skin cancers and minimise unnecessary biopsies have machine learning algorithms that have been trained on datasets containing images of lesions predominantly from fair-skinned individuals. There are concerns that diagnosis may be delayed or negatively affected in patients with darker skin tones, though there is no evidence as yet of actual harm to patients from bias related to the AI algorithms.

Recommendations 4 to 7 are focused on prevention of potential for harm through improved detection of bias in optical devices as a whole, better research and testing tools, more robust monitoring and auditing, and refreshed education of health professionals.

AI-enabled medical devices

AI-enabled medical devices are entering the market at an unprecedented pace. Almost under the radar, their acceptance as ‘routine’ could obscure their potential to generate or exacerbate ethnic and socio-economic inequities in health.

Unfair bias can arise in AI device development and use in several different ways: (i) from the way that health problems are selected and prioritised for AI-related development; (ii) how data are selected for use in developing and testing a device; (iii) how outcomes are defined and prioritised in the healthcare system; (iv) how the underlying AI algorithms driving the device’s functionality are developed and tested and (v) how the device’s impacts are monitored once in use.

The emerging evidence points to a critical need for patients and clinicians to contribute to better articulation and prioritisation of the health ‘problems’ (for the device to solve), and for better AI and health equity literacy that will ultimately help us focus on the best data and outcomes that should count most in possible solutions to these biases. Solutions, whether through the use of more representative training data for the devices or through better monitoring of their deployment to ensure fair outcomes, lie across the lifecycle, and while ‘fairer’ algorithms are being developed for such devices, they are sometimes misguided and a whole-system approach will be necessary to mitigate the bias problem.

To addresses these challenges, Recommendations 8 to 14 have the central aim of enabling the development of safe and equitable AI medical devices.
However, the healthcare and regulatory systems that we inhabit today will not look like the systems of tomorrow with the advent of large language and foundation models (such as ChatGPT) which will disrupt our clinical and public health practice in unpredictable ways. It is imperative that we prepare now for that future. Regulatory bodies like the MHRA will need to be adequately resourced to meet all these challenges. **Recommendation 15** therefore is a call for government action to initiate the thinking and planning that will be needed to face this disruption in relation to AI-enabled medical devices.

**Polygenic risk scores in genomics**

Looking to the future, we reviewed devices in genomics utilising polygenic risk scores (PRS), which are already available commercially (through direct-to-consumer tests), but have not yet been adopted by the NHS. PRS are used, among other factors, to assess risk of diseases that have multiple social, environmental and genetic causes.

There are two equity concerns. First, the major genetic datasets employed by PRS are drawn from populations which are overwhelmingly of European ancestry, which means that the results of PRS may not be applicable for people with other ancestries. This historical ethnic bias is well recognised and there are many important initiatives being taken at national level in the UK to improve the genetic datasets in the long term. We commend these initiatives and focus our recommendations on the second of our equity concerns – the societal challenges.

There are several societal challenges related to the possible introduction of PRS population-wide that have been relatively neglected so far. These include the possible disruption that PRS may bring to long-standing efforts to tackle modifiable risk factors for disease and the vulnerability of PRS information to misinterpretation by the public, particularly mistaken beliefs about genetic determinism. There is also the more immediate challenge for the NHS of dealing with patients’ concerns from PRS tests that are coming into the UK through commercial, direct-to-consumer routes without any regulation or support for the people who receive this sort of information. **Recommendations 16 to 18** require action on these societal challenges.

**Horizon scanning**

We flag up three areas that, though not in scope for this review, cannot be ignored for the future in terms of equity in medical devices. These are the transition of personal ‘wearables’ from well-being devices to medical devices; the wider inequities in access to medical devices that are developing with the advent of the digital device and genomic innovations, and the special circumstances surrounding the medical devices encountered by women in pregnancy and the neonatal period. All these need attention now.
Our recommendations

We make 18 recommendations, detailed below, to address the unfair biases that we identified during the course of our review, aimed at improving equity in medical devices. These improvements now need to be implemented as a matter of priority with full government support.

This review recommends that:

**Recommendation 1:**

Regulators, developers, manufacturers and healthcare professionals should take immediate mitigation actions to ensure existing pulse oximeter devices in the NHS can be used safely and equitably for all patient groups across the range of skin tones. This requires action on several fronts:

- the MHRA should strengthen its guidance for patients and caregivers using oximeters at home, and for healthcare professionals, on the accuracy and performance of pulse oximeters. This should include guidance on taking and interpreting readings from patients with different skin tones. Renewed efforts should be made to promote this guidance to health professionals throughout the NHS and to patients and the public

- health professionals should advise patients who have been provided with a pulse oximeter for use at home to look at changes in readings rather than just a single reading, to identify when oxygen levels are going down and when they need to call for assistance. Patients should also be advised to look out for other worrying symptoms such as shortness of breath, cold hands and feet, chest pain and fast heart rate

- clinical guideline developers and health technology assessment (HTA) agencies such as the National Institute for Health and Care Excellence (NICE) should produce guidance on the use of pulse oximeters emphasising the variable accuracy of SpO\textsubscript{2} readings in patients with darker skin tones, and recommend the monitoring of trends rather than setting absolute thresholds for action

- Health Education England (part of NHS England) and the respective agencies in the devolved nations should educate clinicians about how the technology of pulse oximeters works, and advise that treatment should not be withheld or given on the basis of absolute thresholds alone. Clinicians should be trained to monitor trends rather than absolute thresholds for action based on SpO\textsubscript{2} in patients with darker skin tone, and understand the variable accuracy of SpO\textsubscript{2} levels

- manufacturers of pulse oximeters must update their instructions for use (IFU) to inform patients and clinicians about whether the device is ISO compliant, the limitations of their model of pulse oximetry and any contraindications, and its differential accuracy in patients with different skin pigmentation
Executive summary

• the MHRA should issue updated guidance to developers and manufacturers on the need to make the performance of their device across subgroups with different skin tones transparent.

Recommendation 2:
The MHRA and approved bodies for medical devices should strengthen the standards for approval of new pulse oximeter devices to include sufficient clinical data to demonstrate accuracy overall and in groups with darker skin tones. Greater population representativeness in testing and calibration of devices should be stipulated. The approach should include:

• the MHRA and UK approved bodies following the US FDA in requiring manufacturers to obtain SpO\textsubscript{2} validity data from a diverse subject pool with a) a large number of participants, b) a diverse range of skin tones, and c) a clinically relevant range of oxygenation levels

• manufacturers and research funding bodies commissioning studies that include the population on which the device will be used, subjects with a diverse range of skin pigmentation and critically unwell subjects with poor perfusion. Validation of devices should be conducted in the intended use population and setting, such as at home or in an ICU

• manufacturers of medical grade pulse oximeters being required to comply with BS EN ISO 80601-2-61:2019 (medical electrical equipment – particular requirements for basic safety and performance of pulse oximeter equipment) to gain market approval

• healthcare equity impact assessments being essential requirements for developing or supplying pulse oximeters in the UK, to identify whether mitigating actions are needed to ensure they are fit for purpose for all racial and ethnic groups, and people of varying skin tones. Making these assessments an essential requirement is in line with technological progress and international best practice
**Recommendation 3:**
Innovators, researchers and manufacturers should cooperate with public and patient participants to design better, smarter oximeters using innovative technologies to produce devices that are not biased by skin tone. This could include:

- developing enhanced algorithms for oximeter device software to address measurement bias
- exploring the use of multi-wavelength systems, which measure and correct for skin pigmentation, to replace conventional two-wavelength oximeters

**Recommendation 4:**
The professional practice bodies in the UK, such as the royal colleges, should convene a task group of clinicians from relevant disciplines, medical physicists, public and patient participants, developers and evaluators to carry out an equity audit of optical devices in common use in the NHS, starting with dermatological devices, to identify those at particular risk of racial bias with potential for harm, that should be given priority for further investigation and action.

**Recommendation 5:**
Renewed efforts should be made to increase skin tone diversity in medical imaging databanks used for developing and testing optical devices for dermatology, including in clinical trials, and to improve the tools for measuring skin tone incorporated into optical devices. This will require a concerted effort on several fronts, including:

- encouraging links between imaging databank compilers, professional bodies, optical device developers and clinicians to develop and improve accessibility of imaging data resources that reflect skin tone diversity within the population, such as in databanks for skin cancer diagnosis
- the MHRA providing strengthened guidance to developers and manufacturers on improving skin tone diversity in testing and development of prioritised optical devices. The MHRA is already working towards such guidance as part of its programme on pulse oximeters
- research funders supporting additional incentives and patient-centred approaches to address logistical, financial and cultural barriers which limit participation of ethnic minority groups in clinical studies of optical devices
• researchers and dermatologists developing more accurate methods for measuring and classifying skin tone which are objective, reproducible, affordable and user-friendly. Current practice of using uncertain descriptors of ancestry, ethnicity or race to define patients with dark skin tone is ambiguous and problematic. In its discussions on updating standards, the MHRA is examining which measures would be most appropriate, with the aim of agreeing a consensus. This work is to be commended

**Recommendation 6:**

Once in use, optical devices should be monitored and audited in real-world conditions to evaluate safety performance overall and by skin diversity. This will ensure any adverse outcomes in certain populations are identified early and mitigations implemented. This requires a whole-system approach and should include:

• commitment from manufacturers at the pre-qualification stage to fund and facilitate the establishment of registries for collecting data across all population groups on patient demographic characteristics, use and patient outcomes following deployment of the technology

• HTA agencies (NICE, Scottish Health Technologies Group, Health Technology Wales) being provided with access to post-deployment monitoring and adverse effects data as part of their assessments of optical devices. These data should be considered alongside the wider evidence when determining the value of the optical device for NHS use

• NHS Supply Chain, National Services Scotland, Shared Services Partnership, Procurement and Logistics Service and other contracting authorities including a minimum standard of device performance across subgroups of the target population which will make transparent any equity impacts as part of the pre-qualification stage when establishing national framework agreements. Manufacturers need to declare whether they have considered minimum standards for equity

• DHSC and the devolved administrations updating the national pre-acquisition questionnaire (PAQ) used by NHS trust electrical biomedical engineering (EBME) teams when buying medical equipment to include a minimum designated standard for equity as part of the pre-purchase validation checks
**Executive summary**

- the approved body conducting regular surveillance audits of prioritised optical devices. The audits should include data submissions from the manufacturer and the Medical Device Safety Officer Network or Incidents and Alerts Safety Officer Network (representatives from NHS trusts in charge of reporting on safety), and should include data from the MHRA Yellow Card scheme for reporting adverse incidents and Learning From Patient Safety Events (LFPSE) reporting. These audits should include an evaluation of differential safety by ethnic group.

- the continued strengthening of the MHRA’s vigilance role, as specified in the Cumberlege report’s recommendation 6, which called for substantial improvements in adverse event reporting and medical device regulation, with an emphasis on patient engagement and outcomes.

- better routine capturing of ethnicity data in electronic healthcare records, alongside better collection and collation of data on medical devices in use. This would enable the MHRA to conduct more rapid studies to build the evidence when a hypothesis about potential inequity in an optical device is made.

**Recommendation 7:**

A review should be conducted by the relevant academic bodies of how medical education and CPD requirements for health professionals currently cover equity issues arising in the use of medical devices generally and skin diversity issues in particular, with appropriate training materials developed in response. This should include:

- undergraduate and postgraduate medical and allied health professions training including teaching clinicians about clinically relevant conditions where disease presentation differs between White and ethnic minority patients.

- clinicians being made aware that when using dermoscopy or other medical devices to examine skin lesions, clinical signs may differ according to skin tone, and their training should include images of skin lesions in all skin tones.

- clinicians receiving training in identifying potential sources of bias in medical devices, and in how to report adverse events to the MHRA.

- where new devices are introduced into clinical practice, organisations and clinicians using the new devices ensuring there is sufficient training to acquire skills and competencies before the device is used.
Preventing bias in AI-assisted medical devices

**Recommendation 8:**

AI-enabled device developers, and stakeholders including the NHS organisations that deploy the devices, should engage with diverse groups of patients, patient organisations and the public, and ensure they are supported to contribute to a co-design process for AI-enabled devices that takes account of the goals of equity, fairness and transparency throughout the product’s lifecycle.

Engagement frameworks from organisations such as NHS England can help hold developers and healthcare teams to account for ensuring that existing health inequities affecting racial, ethnic and socio-economic subgroups are mitigated in the care pathways in which the devices are used.

**Recommendation 9:**

The government should commission an online and offline academy to improve the understanding among all stakeholders of equity in AI-assisted medical devices. This academy could be established through the appropriate NHS agencies and should develop material for lay and professional stakeholders to promote better ways for developers and users of AI devices to address equity issues, including:

- ensuring undergraduate and postgraduate health professional training includes the potential for AI to undermine health equity, and how to identify and mitigate or remove unfair biases
- producing materials to help train computer scientists, AI experts and design specialists involved in developing medical devices about equity and systemic and social determinants of racism and discrimination in health
- ensuring that clinical guideline bodies identify how health professionals can collaborate with other stakeholders to identify and mitigate unfair biases that may arise in the development and deployment of AI-assisted devices
- encompassing an appreciation of AI within a whole-system and lifecycle perspective and understanding of the end-to-end deployment and potential for inequity
**Recommendation 10:**

Researchers, developers and those deploying AI devices should ensure they are transparent about the diversity, completeness and accuracy of data through all stages of research and development. This includes the sociodemographic, racial and ethnic characteristics of the people participating in development, validation and monitoring of product performance. This should include:

- the government resourcing the MHRA to provide guidance on the assessment of biases which may have an impact on health equity in its evaluation of AI-assisted devices and the appropriate level of population detail needed to ensure adequate performance across subgroups
- encouraging the custodians of datasets to build trust with minoritized groups and taking steps with them to make their demographic data as complete and accurate as possible, subject to confidentiality and privacy
- developers, research funders, regulators and users of AI devices recognising the limitations of many commonly used datasets and seeking ones that are more diverse and complete. This may require a concerted effort to recruit and sample underrepresented individuals. We commend initiatives internationally and in the UK (such as the National Institute for Health and Care Research (NIHR) led INCLUDE guidance) to encourage the development and use of more inclusive datasets. Data collection by public bodies must be properly resourced so that datasets are accurate and inclusive
- dataset curators, developers, and regulators using consensus-driven tools, such as those by STANDING Together (see box 9) to describe the datasets that are used in developing, testing and monitoring
- regulators requiring manufacturers to report the diversity of data used to train algorithms
- regulators providing guidance that helps manufacturers enhance the curation and labelling of datasets by assessing bias, being transparent about limitations of the data, the device and the device evaluation, and how to mitigate or avoid performance biases
- regulators enforcing requirements for manufacturers to document and publicise differential limitations of device performance, and where necessary to place reasonable restrictions on intended use
- the Health Research Authority and medical ethics committees approving AI-enabled device research making sure they do not impose data minimisation constraints, which could undermine dataset diversity or the evaluation of equity in the outcomes of research
Recommendation 11:
Stakeholders across the device lifecycle should work together to ensure that best practice guidance, assurance and governance processes are co-ordinated and followed in support of a clear focus on reducing bias, with end-to-end accountability. This should include:

- the MHRA adjusting its risk assessment of AI-assisted devices, so that all but the simplest and lowest risk technologies are categorised under Class IIa or higher, including a requirement for their algorithms to be suitable for independent evaluation, the use of a test of overall patient benefit that covers the risks of biased performance, and a requirement for manufacturers to publish performance audits with appropriate regularity which include an assessment of bias
- supporting health professionals’ involvement early in the development and deployment of AI devices. We commend the use of ethical design checklists which may assist in the quality assurance of these processes
- manufacturers adopting the MHRA’s Guiding Principles for Good Machine Learning Practice for Medical Device Development
- all stakeholders supporting the MHRA Change Programme Roadmap, such as promoting the development of methodologies for the identification and elimination of bias and testing the robustness of algorithms to changing clinical inputs, populations and conditions
- placing a duty on developers and manufacturers to participate in auditing of AI model performance to identify specific harms. These should be examined across subgroups of the population, monitoring for equity impacts rather than just unequal performance

Recommendation 12:
UK regulatory bodies should be provided with the long-term resources to develop agile and evolving guidance, including governance and assurance mechanisms, to assist innovators, businesses and data scientists to collaboratively integrate processes in the medical device lifecycle that reduce unfair biases, and their detection, without being cumbersome or blocking progress.
**Recommendation 13:**
The NHS should lead by example, drawing on its equity principles, influence and purchasing power, to influence the deployment of equitable AI-enabled medical devices in the health service. This should include:

- NHS England and the NHS in the devolved administrations including a minimum standard for equity as part of the pre-qualification stage when establishing national framework agreements for digital technology
- NHS England updating the digital technology assessment criteria (DTAC) used by health and social care teams when buying digital technology to recommend equity as part of the pre-purchase validation checks
- working with manufacturers and regulators to promote joint responsibility for safety monitoring and algorithm audits to ensure outcome fairness in the deployment of AI assisted devices. This will require support for the creation of the right data infrastructure and governance

**Recommendation 14:**
Research commissioners should prioritise diversity and inclusion. The pursuit of equity should be a key driver of investment decisions and project prioritisation. This should incorporate the access of underrepresented groups to research funding and support, and inclusion of underrepresented groups in all stages of research development and appraisal. This should include:

- requiring that AI-related research proposals demonstrate consideration of equity in all aspects of the research cycle
- ensuring that independent research ethics committees consider social, economic and health equity impacts of AI-related research

**Recommendation 15:**
Regulators should be properly resourced by the government to prepare and plan for the disruption that foundation models and generative AI will bring to medical devices, and the potential impact on equity. A government-appointed expert panel should be convened, made up of clinical, technology and healthcare leaders, patient and public involvement (PPI) representatives, industry, third sector, scientists and researchers who collectively understand the technical details of emerging AI and the context of medical devices, with the aim of assessing and monitoring the potential impact on AI quality and equity of large language and foundation models.
Future proofing: polygenic risk scores

**Recommendation 16:**

The focus of PRS studies should be widened beyond genetic diversity to include the contribution of the social determinants of health – including lifestyle, living and working conditions and environmental factors such as air pollution – to overall disease risk, and how these affect the predictive potential of PRS among different ethnicities and socio-economic groups.

Developments with this wider research focus should aid the refinement of overall risk assessments so they better reflect the role that PRS play alongside non-genetic risk factors.

**Recommendation 17:**

National research funders should commission a broad programme of research and consultation with the public, patients and health professionals to fill the gaps in knowledge and understanding concerning PRS. The programme should cover both the public’s understanding of the nature of genetic risk and the meaning of the PRS they are presented with, together with explorations of how health professionals interpret these risks and can best communicate and support people in understanding the results of their PRS.

The research programme should cover impacts on diverse population sub-groups, and be informed by extensive engagement with the public and patients to gain their perspectives.

Results from this research programme, together with actions on recommendation 16, should feed into the development of clinical applications for PRS medical devices, covered in recommendation 18.

**Recommendation 18:**

UK professional bodies such as the royal colleges and the health education bodies across the UK should develop guidance for healthcare professionals on the equity and ethical challenges and limitations of applying PRS testing in patient care and population health programmes.

The guidance should:

- include the interpretation of risk scores, communicating risk to patients and the public and counselling and support
- be informed by extensive public and patient engagement
1. Panel overview and approach

Our task

A core responsibility of the NHS is to maintain the highest standards of safety and effectiveness of medical devices available for all patients in its care. Evidence has emerged, however, about the potential for racial and ethnic bias in the design and use of some medical devices commonly used in the NHS, and that some ethnic groups may receive sub-optimal treatment as a result.

In response to these concerns, the former Secretary of State for Health and Social Care, the Rt Hon Sajid Javid MP, commissioned this Independent Review on Equity in Medical Devices.

The purpose of the review was to establish the extent and impact of potential racial, ethnic and other factors leading to unfair biases in the design and use of medical devices and to make recommendations for improvements. The terms of reference are given in appendix A.

Scope

In the context of assessing where potential racial and ethnic bias exists and the impact across the population, the review focused on those products classified as medical devices under current GB and EU regulations and in use across the UK. The review was also future-focused and considered the enhanced risk of bias in the emerging range of AI tools, as well as medical devices involving genomics. Section 5 provides a more detailed summary of the scope of the review and the medical devices considered by the panel.

The review panel was asked to make an assessment in relation to the following questions, which have informed our work over the past 15 months:

- how far reaching is the problem?
- where medical devices do not function equally well for all racial or ethnic groups, is the scale of this difference of clinical significance, and could it cause adverse health outcomes for some racial or ethnic groups?
- what could be done to mitigate such adverse outcomes?
- how effective are any such mitigations?
- what further action should be taken to address these issues?
In addition, the review was asked to make recommendations in relation to preventing potential racial, ethnic and other inequities related to the design and use of medical devices, including unintended or implicit bias. These recommendations cover:

- how to address potential racial, ethnic and other unfair biases, including through a whole-system approach, from design to use
- the role regulation could and should play in identifying, mitigating or eliminating identified bias
- what systems need to be in place to ensure emerging technologies, including software as a medical device and AI as a medical device, are developed without inbuilt racial, ethnic and other unfair biases
- how the UK can drive forward international standards to improve healthcare and promote equity in the design and use of medical devices

Establishing the independent review

In January 2022 Professor Dame Margaret Whitehead was appointed as the review chair. The following experts joined the Independent Review panel in March 2022: Professor Raghib Ali, Professor Enitan Carrol, Professor Chris Holmes and Professor Frank Kee (please see appendix B for their biographies).

The review has been supported by a secretariat at the DHSC including Dr Aleksandra Herbec, Maya Grimes, Sia Thieba and Jessica Scott. Dr Lisa Cromey also joined us on secondment from the Northern Ireland Postgraduate Specialist Training Scheme in Public Health. Additional DHSC team members contributed to various tasks of the review.

Our approach

From the start we have taken a broad approach to gathering and reviewing the evidence, learning not only from academics and the scientific literature but also from the many stakeholders involved in developing, testing and regulating medical devices on the one hand, and the users of the devices on the other, including NHS planners and policy advisers, health professionals providing frontline services, educators and trainers and, of course, the ultimate users: patients and the public.

At the heart of everything we did were the needs, rights and experiences of patients and the public. We were clear that our review was not an abstract scientific study but an investigation into the impact of bias and its widespread and often serious consequences for individuals and groups.

For example, we commissioned experts to provide the panel with scenarios demonstrating how bias in particular devices – often compounded by existing inequities in healthcare and wider society – undermine the quality of care people receive.
1. Panel overview and approach

We also paid particular attention to the information and insights provided by individuals and patient groups through our engagement with stakeholders (see appendix C) and call for evidence (see appendix D).

Since embarking on our review we have:

- collated and reviewed the scientific literature on the existence, causes and consequences of ethnic and other unfair biases in medical devices
- commissioned rapid reviews of the evidence of potential bias and clinical impact of devices in our three selected types – optical devices, AI-enabled medical devices and polygenic risk scores – from experts in the respective fields
- illuminated the patient perspective by commissioning a rapid review of the evidence on the medical devices that pregnant women encounter during pregnancy and the neonatal period, following the patient pathway
- commissioned four ‘patient perspective’ scenarios, following the experience of patients from different ethnic and socio-economic backgrounds through their encounters with medical devices during the course of NHS treatment for four different health conditions
- engaged with over 150 stakeholders involved in developing, using or evaluating medical devices through virtual calls, in-person meetings, written submissions and follow-up correspondence
- attended a series of relevant scientific and policy conferences
- run a public call for evidence
- undertaken landscape mapping of nearly 300 recent and current initiatives and academic outputs on identifying and tackling unfair biases in medical devices
- scoped 86 UK and international initiatives currently underway of relevance to the issue of equity in medical devices
- reviewed and analysed nearly 700 recommendations on our three selected device types from the scoped initiatives and literature reviews
- held six roundtables with stakeholders to test our draft recommendations
- co-produced a 2.5-minute animation with a research patient and public involvement (PPI) panel to explain the findings of our review to a lay audience

Further information on the activities of the review, including acknowledgements for a full list of stakeholders who have contributed, is set out in appendix C. Information on the call for evidence and summary of responses is presented in appendix D.
2. Concepts of race and ethnicity

The terms ethnicity and race are often used interchangeably, which leads to confusion among researchers. Ethnicity is usually reserved for classifying humans on the basis of characteristics related to culture, whereas race focuses on biologically-based traits and characteristics. The issue is complex, and for the purposes of the Independent Review, we outline our approach here.

Race refers to the group a person belongs to as a result of a mix of physical features such as skin colour and hair texture, which reflect ancestry and geographical origins, as identified by others or, increasingly, as self-identified. The importance of social factors in the creation and perpetuation of racial categories has led to the concept broadening to include a common social and political heritage, making its use similar to ethnicity. Race and ethnicity are increasingly used as synonyms, causing some confusion and leading to the hybrid terms race/ethnicity.

Ethnicity refers to the social group a person belongs to, and either identifies with or is identified with by others, as a result of a mix of shared cultural and other factors including language, diet, religion, ancestry and physical features traditionally associated with race.²

The NHS Race & Health Observatory developed five principles to be followed when writing and talking about race and ethnicity: be specific, avoid acronyms, be guided by context, be transparent about approach, and be adaptable.³ In this Independent Review, we adopt these principles throughout the report.

We also discuss some of the relevant challenges on considering ethnicity, race and health equity as described by Bhopal (2004) in the light of this review, such as:

- recognition of heterogeneity within ethnic minority groups. With regards to this review, this is particularly relevant for skin tone and genetic predisposition, which can vary widely within a particular ethnic group
- identification of representative populations on which the devices have been developed. For example, data from African Americans may not be representative of Black British or diasporan Africans
- avoiding misinterpretation of differences that are attributable to confounding variables, for example, socio-economic status or access to healthcare (private or insurance-funded healthcare versus NHS)
presentation of research to achieve benefits for the population studied, and avoid stigmatisation and racism. Indeed, this is the aim of this Independent Review, to ensure equity in health outcomes of medical devices irrespective of ethnicity or skin tone

**Terminology used in this report**

In this review, the definition of ‘ethnic’ bias is based on social group a person belongs to, and either identifies with or is identified with by others, as a result of a mix of cultural and other factors including language, diet, religion, ancestry, and physical features traditionally associated with race. We use the term ‘ethnic bias’ to describe situations where medical devices do not work as well for some ethnic groups as a result of differences in biological characteristics, genetic predisposition, or under-representation in research.

There are recognised biological differences between different ethnicities, which may affect the function or interpretation of results from medical devices. These differences extend beyond skin tone, and may include, for example, bone density, lung volume, kidney function and blood pressure regulation. Examples are:

- individuals of Black ethnicity have a greater bone mineral density and body protein content than do those of White ethnicity, resulting in a greater fat-free body density. There are also racial differences in the distribution of subcutaneous fat and the length of the limbs relative to the trunk\(^5\)
- evidence suggests that transepidermal water loss is greater in individuals with Black skin compared with White skin. Microscopic evaluation reveals that skin from Black individuals contains larger mast cell granules, and differences in structural properties and enzymes of mast cells compared with skin from White individuals\(^6\)
- significant ethnic and sex differences in the prospective relationship between heart rate variability and blood pressure change. These findings may give clues as to the underlying mechanisms that are involved in the well-known disparities in blood pressure and hypertension-related cardiovascular diseases\(^7\)
- greater diurnal blood pressure variability, including dynamic surges, in Japanese compared with Black and White patients may indicate ethnic differences in the underlying blood pressure regulatory mechanism of resistant hypertension\(^8\)

In the context of this review, we attempt to relate the definitions above to the specific context of medical devices when considering potential bias in each category of device.

Optical devices – in pulse oximeters and bilirubinometers, for example, the potential bias is against people with darker skin tone, which relates to physiological differences between population groups rather than their social or cultural identities. In the context of the definitions above, this is a racial bias.

AI-enabled applications – the under-representation of certain ethnicities in datasets results in algorithms that create bias towards other populations. Machine learning algorithms developed exclusively on one population group might translate poorly
2. Concepts of race and ethnicity

Beyond that population, resulting in bias. Individuals of African ancestry, Latinos and Asians have a higher burden of primary open angle glaucoma compared with those with European ancestry, yet in a review of publicly available imaging datasets in ophthalmology used for machine learning, ethnicity was reported in less than 20% of datasets. In the context of the definitions above, this is an ethnic bias.

Similarly, in a review of publicly available skin image datasets, patient ethnicity and skin tone (Fitzpatrick skin type) data were available in less than 5% of images. Darker skin tones represented less than 1% of the dataset. Use of these datasets in machine learning algorithms would result in significant bias against darker skin tones, given that prevalence, presentation and types of skin cancer vary across populations. In the context of the definitions above, this is a racial bias.

In contrast, the potential bias in some AI applications in determining risk of cardiovascular disease or diabetes may be against people from particular ethnic minority groups who share a common diet, or cultural way of life, for example, and assumptions about associated health risks may be built into the algorithms, with or without supporting evidence. In the context of the definitions above, this is an ethnic bias.

Genomics and their relationship with racial and ethnic bias

The ability to accurately report whether a genetic variant is associated with an outcome or disease is more difficult in people of predominantly non-European ancestry, as there are far fewer data from populations of non-European ancestry. Consequently, genomic tests could be biased against people of predominantly non-European ancestry.

Genetic ancestry refers to information about the people that an individual is biologically descended from, including their genetic relationships. Knowledge of a person’s ancestry can help determine frequencies of genetic risk variants, which may vary with ancestry. In most genetic studies, genetic ancestry information has replaced the use of racial categories because it is more accurate compared with self-reported ancestry.

‘Ancestry’ is not equivalent to ‘race’, but in the context of polygenic risk scores (PRS) (see section 8), ‘shared ancestry’ could be interpreted as race, especially when genetic ancestry is traced back to the major continents of Africa, Asia, Europe, and the Americas, which inadvertently leads to the entangling of ancestry with race in genetic studies. In the context of the definitions above, this is a racial bias.

In summary, in this review, we use ‘racial and ethnic bias’ to cover the concepts of race and ethnicity, depending on context of device use.
2. Concepts of race and ethnicity

**Relationship between ethnicity and socio-economic status**

In considering ethnic inequities in health it is also important to look at socio-economic disadvantage, as there are strong associations between the two. As socio-economic disadvantage is a major risk factor for most health outcomes, and differs significantly by ethnicity, it should also be taken into consideration when making comparisons between ethnic groups.

For example, the relationship between ethnicity and socio-economic status or disadvantage is complex as there is a wide variation between ethnic groups. UK statistics show:\(^{15, 16}\)

- Bangladeshi, Pakistani and Black groups are the most likely to be living in deprived neighbourhoods
- unemployment rates are highest among Black and Bangladeshi/Pakistani populations while White and Indian groups are more likely to be in employment
- Bangladeshi, Pakistani, Chinese and Black groups are about twice as likely to be living on a low income, and experiencing child poverty, as the White population. Most groups had a higher proportion of women in low pay than men, with a stark gender difference in the White population (31% of women earning below the living wage compared with 16% for men)
- ethnic minority groups are more likely to live in private rented accommodation than the White British population (a third vs 18%), and in overcrowded households (13.5% vs 2.8%), with 30.2% of Bangladeshi households being overcrowded
3. What does ‘striving for equity in medical devices’ mean?

A fundamental goal of the NHS is to make healthcare available to everyone equitably. During our review, many people have stressed the importance of clarifying what the terms ‘equity’ and ‘fairness’ mean in the context of health services in general and medical devices in particular, because there is widespread confusion about what these terms mean.

The foundation of the NHS is that it is a basic human right to have access to healthcare that supports us in keeping mentally and physically well, helps us recover when we are ill and, when we cannot fully recover, to stay as well as we can until the end of our lives.  

**Equity in the NHS system**

There are many components of the NHS that combine to make it fair and equitable, as depicted in Figure 1. These equity components are interconnected, so altering the arrangements for one element may have an impact on other parts of the system.
3. What does ‘striving for equity in medical devices’ mean?

**Figure 1: Equity elements in the NHS**

- **Universal eligibility**: Same high standard of care for everyone.
- **Fair financing/pooling risk**: Selection on basis of need.
- **Free at point of use**: Inclusive coverage of comprehensive range of services.
- **Comprehensive geographic coverage**: No exploitation of patients for profit.
- **Same high standard of care for everyone**: Universal eligibility.
- **Selection on basis of need**: Fair financing/ pooling risk.
- **Inclusive coverage of comprehensive range of services**: Free at point of use.
- **Comprehensive geographic coverage**: No exploitation of patients for profit.

Source: adapted from Whitehead, 1994

The first equity element is universal entitlement. There are no eligibility hurdles or means tests. Everyone has the right to register with a GP and, through that registration, gain access to the whole system when in need.

The next three elements aim to ensure economic access. There is a fair financing system, with financial risk pooled through general taxation. People contribute to the financing of the NHS according to their means, and benefit according to their needs. It is free at the point of use, and health professionals are rewarded in ways that avoid incentives to exploit patients for profit.

The next two elements are concerned with equity in geographic access to services and inclusive coverage of a comprehensive range of health conditions across the course of our lives.
The seventh element embodies the fundamental principle of selection for treatment based on clinical need, not ability to pay or any other social advantage.

The final element is that the same high standard of care should be offered to everyone, without discrimination with respect to social status, ethnicity, gender or age. This principle precludes two-tier services with poorer, less effective services offered to less privileged groups, while more privileged get access to the best services.

This principle also encompasses equity of cultural access, holding health workers to providing the same high standards of respect and dignity for everyone, irrespective of a patient’s social status. Do some groups experience cultural barriers to access, rendering services unacceptable even when available? Do language barriers or cultural practices prevent some ethnic minority groups from accepting the available care? Do health workers strive to provide the same high standards of respect and dignity for everyone, whatever their circumstances and backgrounds?

Matching services to need

A key goal of healthcare equity is to match services to the level of need. This may result in large differences in access to, and use of services between different population groups, to support the more disadvantaged in greater need. This contrasts with the goal of equality which, in the context of health services, would result in everyone getting the same level of service irrespective of their need. See Figure 2.
3. What does ‘striving for equity in medical devices’ mean?

**Figure 2: Equality versus equity**

![Image showing the difference between equality and equity](image)

Source: image adapted from Interaction Institute for Social Change, Artist: Angus Maguire.

Inequity arises when the principle of matching services to need is broken. This can be seen in the inverse care law, where “the availability of medical care is inversely related to the need for that care in the population served”.¹⁹ First identified in healthcare in the Welsh mining valleys, this ‘law’ identifies the common trend for services to be fewer and of lower quality for more disadvantaged groups and areas, which have poorer health profiles.

**Applying the equity principles to medical devices**

Access to medical devices that function equitably across the population contributes to the fairness of the whole system. For example, medical devices approved for use in the NHS should:

- be available to everyone in proportion to need
- support the selection of patients for treatment based on need and risk
- function to the same high standard and quality for all relevant population groups. If there are unavoidable differences in performance in relation to some groups, these need to be understood and mitigated, such as in how a device is calibrated.
3. What does ‘striving for equity in medical devices’ mean?

The inverse care law in digital devices

There are many examples of inequity in medical devices. For example, the inverse care law operates in digital health technologies and services. A marked digital divide is emerging between those who can take advantage of healthcare technology and those who face barriers to using it, even though they may have higher risk or need.

Patients with higher socio-economic status are more likely to use online mental health and substance abuse intervention tools, despite higher incidence rates among those with lower socio-economic status. Digital health interventions create inequities because they are more accessible to, heavily used by, adhered to, or effective for those from socio-economically advantaged groups. This can lead to poorer health outcomes for underserved and disadvantaged groups.

Bias in the selection of patients

Systematic bias in selecting patients at high risk for more advanced treatment may lead to inadequate care. If a diagnostic or screening test inadvertently gives results that are biased against a particular population group, then patients in that group may not be offered the treatment that the severity of their condition warrants.

A commercial risk prediction tool in US healthcare infamously led to systemic discrimination against Black patients, who tended to be far sicker than White patients at an equivalent risk score. The problem was that the designers of the tool chose healthcare costs as a measure of ill health. But in the US private healthcare system, more affluent people with comprehensive health insurance have higher healthcare costs irrespective of their level of ill-health, so this tool effectively selected patients for more intensive treatment based partly on their income. Correlations between socio-economic status and ethnicity mean Black patients in the US are less likely to run up the same healthcare costs as more advantaged White patients. The result was that the algorithm identified White patients as having higher risk scores and were more often selected to receive additional care compared with equally sick Black patients.

Biases in performance

If the performance of a device is found to differ for men and women, for example, or be poorer for some ethnic groups, patients may be harmed if mitigating action is not taken. Here, equity becomes a matter of safety.

A device that performs differently for men and women is the ventilator which enhances the delivery of oxygen to the lungs. Women’s lungs tend to be smaller, but the default settings on the ventilators are for men. This bias is overcome by the clinical team remembering to adjust the settings to prevent the machine damaging a female patient’s lungs.

A test used to assess the health of newborn babies has an element that depends on judging skin colour. The Appearance, Pulse, Grimace response, Activity and Respiration (APGAR) score is used in the minutes immediately after birth to judge if extra medical
care or emergency intervention such as resuscitation is needed. Part of the score measures any sign of abnormal pallor or changes in skin colouration, but this only works for babies of light skin tones. This may result in a failure to identify when a baby with darker skin tone needs urgent medical intervention.

**The unfairness of ‘fairness metrics’**

Sometimes attempts to correct for bias built into medical devices make the situation worse. For example, there are several instances of this where well-meaning attempts to devise ‘fairness metrics’ for machine learning in AI have resulted in disadvantaging the very groups the efforts were designed to help.

This sort of mistake comes about through misunderstanding the concept of healthcare equity. These AI developers mistakenly equate equity with equality, and come up with adjustments to algorithms that simply equalise performance or outcomes between socio-demographic groups, taking no account of differences in healthcare need. These attempts at equalisation can even result in ‘levelling down’, where fairness is achieved by making every group worse off. This violates the central tenet of health equity, which is to level up – reduce the health gap by bringing the health of worse off groups closer to those who are better off.
4. How do unfair biases in medical devices come about?

To understand how and why inequity and unfair biases in medical devices emerge, we considered the whole of the medical device ecosystem, which in turn needs to be placed in its context of broader societal influences that feed into every stage of the device lifecycle.

Figure 3 depicts the framework we have adopted for considering the points at which unfair bias can be introduced or amplified.
4. How do unfair biases in medical devices come about?

**Figure 3: Entry points for bias in the medical device ecosystem**

<table>
<thead>
<tr>
<th>Real-world health inequities and injustices</th>
<th>'Baked-in' discrimination in data</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Historical inequities and social determinants of health</td>
<td>• Unrepresentative datasets</td>
</tr>
<tr>
<td>• Structural biases</td>
<td>• Sampling biases</td>
</tr>
<tr>
<td>• Inequities in access and treatment</td>
<td>• Poor data quality</td>
</tr>
<tr>
<td>• Failure to consider needs/experiences of diverse populations</td>
<td>• Inconsistency in data collection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inequities in clinical use</th>
<th>Biased design and development</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Lack of training of health professionals in equity issues in devices they use</td>
<td>• Physical bias in hardware</td>
</tr>
<tr>
<td>• Failure to evaluate and pick up differential performance and safety post-deployment</td>
<td>• Computational bias in software</td>
</tr>
<tr>
<td>• Poor routine recording of ethnicity data and bias in patients’ notes feed into datasets for device development</td>
<td>• Biased recruitment into clinical trials and testing of devices</td>
</tr>
<tr>
<td></td>
<td>• Standards set for devices don’t take differential performance into account</td>
</tr>
</tbody>
</table>

Source: adapted from Leslie and others, 2022

The figure shows an ‘unvirtuous circle’ in which injustice and health inequities originating in the real world are carried into the production and use of medical devices, where further bias may be introduced at various points in the device lifecycle. It can come full circle when using specific medical devices may, in extreme circumstances, bring about injustices in wider society.
4. How do unfair biases in medical devices come about?

Real-world patterns of health inequity and injustice

The ‘world’ in the first quadrant refers to the social and historical context in which the social determinants of health are situated and where societal patterns of structural bias and social injustice arise. Such patterns, prejudices and attitudes can be encoded in datasets which are then drawn into every stage of the medical device lifecycle, and perpetuated, reinforced or exacerbated through biased choices made in device development and research.

Long-established socio-economic and ethnic inequities in UK health generate a greater need for healthcare among more disadvantaged and marginalised groups through:

- higher levels of ill health
- the inverse care law – historic under-provision in disadvantaged localities and for less privileged socio-demographic groups
- poverty and discrimination making access to services more difficult
- poorer living conditions and nutrition making it more difficult to maintain a good quality of life during chronic illness and to recover from periods of ill health

While this extra need for healthcare is generated by social conditions such as low-income, jobs and housing, the health system still needs to address their effects. Otherwise the NHS falls into the trap of the inverse care law, with those in greatest need or with the highest risk experiencing poor access to services such as screening and diagnostic tests as well as treatment.

Beyond the heightened need for healthcare are the effects of patterns of discrimination and social injustice that can be transferred into medical device research, design, development and deployment. These include the stereotyping and bias in medical knowledge that leads to knowledge gaps and the neglect of medical research that would benefit less privileged groups. Entrenched misconceptions of biological differences between ethnic groups can feed into the application of faulty ‘race correction factors’ to diagnostic tools, that can then lead to flawed decisions about a patient’s care which could result in harm.28

Perceptions of race can unfairly influence the treatment people receive.29 For example, a test for elevated levels of creatinine in the blood is used to diagnose chronic kidney disease, but until recently the level needed for diagnosis was higher for Black patients than for White. This flawed assumption about kidney disease in Black patients went largely unchallenged for decades, but modern analysis indicates that using a higher level harms Black patients by withholding treatment until their kidney disease is more advanced.30, 31, 32
4. How do unfair biases in medical devices come about?

A failure to consider the needs and experiences of diverse populations influences the whole device ecosystem, including the selection of problems to be researched, the choice of innovations prioritised for development, where research and development money is invested, what data infrastructure is developed and the value placed on equity in the setting of standards and safety regulations.

‘Baked-in’ discrimination in data

Discrimination can be baked-in to the data on which medical devices are based. The data sources on which the development of medical devices draw often fail to accurately represent marginalised and underserved communities.

This may be because some groups have poorer access to healthcare systems, because they distrust clinical and research environments, or they have limited access to, for example, digital platforms on which data are collected. Researchers may overlook some population groups during data collection, which tends to favour the interests of privileged and dominant groups, leading to sampling and selection bias. The inferences drawn from unrepresentative data may be limited or misleading.

For example, a large study of two x-ray datasets used to diagnose thoracic diseases found women to be underrepresented. This led to lower accuracy rates when diagnosing women until more women were added to the datasets.33

Biased design and development

Unfair bias can be introduced at various stages of design and development. For some technologies there is physical bias inherent in the mechanics of the hardware. The mechanism on which the device is based can lead to differential performance, such as when using infrared light through skin to detect physiological abnormalities. The light reacts differently to shades of skin tone and, if not taken into account, may not work as well with patients with darker skin tones.34

There is also computational bias in the software or datasets used to develop AI algorithms. Software developers may unconsciously take biased data from highly skewed sources. If this bias is not mitigated it will then be perpetuated and propagated by the algorithm. This can have harmful consequences. In a diagnostic test, for example, favouring one group over another could lead to an algorithm diagnosing the favoured group more accurately, or failing to diagnose the neglected group.

During testing of new medical devices, groups may be underrepresented in recruitment into clinical trials and evaluations of the device. Trials often do not include representative proportions of women, ethnic minorities and people with a low socio-economic status,35 which makes it difficult to determine which devices are applicable, safe and effective for which groups.
4. How do unfair biases in medical devices come about?

Even in studies where the ethnicity and socio-economic status breakdowns of participants are recorded, it is rare for the trial outcomes to be analysed and reported with explicit regard for these variables. The opportunity to detect differential performance of devices by ethnic and socio-economic group is therefore lost.

Standards for devices may not take into account differential effectiveness across different groups in the population and so devices may be approved for market by regulators which have poorer performance for some than for others or with statements of ‘intended use’ that effectively exclude segments of the population.

**Inequities in clinical use**

Further biases may arise once the medical device is in use. Healthcare professionals may not understand potential biases and how to mitigate the risks. Much of today’s education, training and professional development does not equip them with the knowledge and skills to identify and address equity issues, while clinical guidelines may not specify mitigating actions. This can result in the wrong interpretation of test results, and lead directly to patient harm.

In contrast with safety monitoring for new drugs, post-deployment surveillance, such as monitoring and auditing, are often not robust enough to detect safety issues such as differential clinical impact or adverse events affecting a particular group of patients.

This issue is compounded by poor recording of racial, ethnic and other socio-economic characteristics in patient records or stereotypes reinforced in patient notes, which are then incorporated into AI algorithms, providing further sources of bias.

Completing the unvirtuous circle, widespread misinterpretation of results from a medical device could, in extreme circumstances, provoke discrimination in society. It is possible to imagine a scenario where, for example, misinterpretation of results from widespread genetic testing exacerbates discrimination against a marginalised group.

**The perspective of patients**

Many of these biases are inadvertent – developers and users of medical devices do not set out to discriminate against a particular group in the population, and once they realise that this may be happening they attempt to put things right. ‘But you can’t know what you don’t know.’ The scenario in Box 1 follows the experience of patients coming to health services with acute respiratory illness. It illustrates the multiple entry points for inequity and bias in the use of medical devices that can arise during patients’ journeys through the system.
4. How do unfair biases in medical devices come about?

**Box 1: the impact of medical device inequities on patients’ experiences with acute respiratory illness**

Steven, a 58-year-old White British man, has been experiencing worsening breathlessness, fever and chest pain. He arrives at his office, sweaty and breathless, and with a new cough. His manager calls 999. Paramedics attend and find him so breathless that they rush him to the nearest emergency department. A PCR test for COVID-19 is positive, and his chest x-ray shows severe pneumonitis. A pulse oximeter shows his blood oxygen levels are low. The emergency team assesses him using a standard clinical risk prediction score, which shows a very high score. The hospital’s protocol for scores this high means that he is referred to the intensive care unit (ICU) to receive respiratory support called CPAP (continuous positive airway pressure) via a tight-fitting face mask. This treatment reduces the need for patients with severe COVID-19 to be put on a ventilator. He is seriously ill for a few days, but makes a good recovery. He goes home after 10 days.

Yvonne, a 60-year-old Black British woman of Caribbean heritage, has similar symptoms and is barely able to manage her job as a cleaner because of her breathlessness. As an agency worker she has no sick pay, so she delays calling 999 until she is home from work. Paramedics find her so breathless that they take her straight to the nearest emergency department. A PCR test for COVID-19 flags positive, and her chest x-ray shows severe pneumonitis. A pulse oximeter shows her blood oxygen levels are just within normal range. The emergency team assesses her using a clinical risk prediction score, which comes back high, but not sufficiently high to trigger referral to intensive care.

Further tests show her oxygen levels are worse than the pulse oximeter suggests. She is finally moved to intensive care where the team tries to help her breathing with a CPAP machine, but the face mask is too large and doesn’t fit her properly. Her oxygen levels are now critically low, so she is put on a ventilator to save her life.

After she is sedated, the intensive care doctor inserts a breathing tube and turns on the ventilator. Its default settings are for men, so the team needs to remember to adjust these to prevent the machine damaging her lungs. Injury to her kidneys goes unnoticed for several days because the hospital still uses an outdated racial ‘correction’ which is known to disadvantage Black patients. This leads to her needing temporary dialysis via tubes inserted into veins in her neck. After a prolonged ICU stay she is discharged home, but suffers with chronic shortness of breath.
4. How do unfair biases in medical devices come about?

The healthcare pathways described here have a high reliance on medical devices and demonstrate how harm may occur through an accumulation of socio-economic factors, historical medical misconceptions and inequity directly related to the performance or provision of those devices, both hardware and software.

Source: scenario prepared for the independent review by Dr Joseph Alderman and Professor Alastair Denniston, December 2022.
5. Focusing the equity lens

The government’s definition of what counts as a ‘medical device’ for the purpose of UK regulation is “any apparatus, appliance, software, material or other article, whether used alone or in combination, intended by the manufacturer to be used by human beings for a medical purpose”.

This definition is wide-ranging, extending from hardware such as walking sticks, hospital beds and contact lenses to in vitro diagnostic devices used to test blood or tissue samples, software such as AI-assisted clinical decision-making tools and disease risk assessment tools in genomics. It also includes active medical devices such as cardiac pacemakers which are implanted in the patient.

In effect, medical devices cover most things used in healthcare except pharmaceuticals, which have a separate system of development, testing and regulation. When considering the scope and purpose of the review we included those products classified as medical devices under current UK and international regulations that are used in the NHS throughout the UK. In addition, the review considered the growing risk of bias in devices on the horizon in fields such as genomics, poised for introduction to the NHS in the coming years.

Focusing the equity lens on three types of device

From an early scoping of the medical device landscape and consultation with clinicians, we identified three types of medical device that may be particularly prone to racial, ethnic or other unfair biases, borne out by high-profile studies. We decided to concentrate on these three types in our assessment of the evidence.

Focus on optical devices

The first type is what we have termed ‘optical devices’. These use light of different wavelengths to detect underlying signals of disordered physiology. Potential racial bias arises in part from the basic physics of such devices, in which the light processes built into the hardware react differently with different skin tones, potentially causing performance differences depending on the patient’s skin tone.

The pulse oximeter is a prominent example. The initial stimulus for this review was scientific and media concern during the COVID-19 pandemic that pulse oximeters – which measure the level of oxygen in a patient’s blood – may be less accurate for people with darker skin, overestimating the level of oxygen in the blood and therefore potentially under-estimating the severity of their illness and undermining their treatment. This inferior performance would violate the equity principles of the NHS.
We therefore began our work by examining the scientific evidence for potential ethnic bias in pulse oximeters in greater depth and, crucially, whether any bias had clinical impact.

Other optical devices using light to obtain oxygen measurements were also reviewed, along with dermatological devices used in diagnosing skin conditions such as skin cancer, the performance of which may vary by skin tone or pigmentation. Our findings and recommendations on optical devices are presented in section 6.

**Focus on artificial intelligence-enabled medical devices**

The second type is AI as a medical device (AlaMD). AI encompasses the use of computers to perform tasks that normally require human intelligence. Use of AI to aid decision-making is becoming pervasive in healthcare, but these devices are often invisible to patients. The MHRA has given regulatory clearance through its registration scheme to a mounting number of AI-assisted devices.

AlaMDs are already demonstrating their effectiveness at improving the accuracy and speed of diagnoses, evaluating risk and making decisions about treatments. But there is growing concern about their ability to inflict harm. In machine learning, for example, the AI models are only as good as the data fed into them, and if those data are unrepresentative of minority groups or biased in some other way against population subgroups, the models may ‘learn’ biases engrained in medical practice and exacerbate existing health inequities.

High profile cases outside the health sector have been shown to disadvantage women and people from ethnic minorities and poorer groups due to faulty assumptions built into the models, and may have triggered distrust in AI more generally (see Box 2). In the NHS, such unfair biases would violate equity principles by going against the selection of patients for essential treatment based on need, or by offering some groups devices of inferior performance or quality. Findings and recommendations on AlaMDs are presented in section 7.

**Focus on future-proofing polygenic risk scores**

Looking to the future, the third device type in our assessment relates to those based on genomics and PRS. These are already available commercially through direct-to-consumer tests but have not yet been adopted by the NHS. PRS are used, among other functions, to assess risk of diseases that have multiple social, environmental and genetic causes.

PRS differ in important respects from the genetic tests already in use in the NHS. Genetic testing is well-established for rare pathogenic genetic variants in individual genes that cause specific genetic diseases or carry a very high risk of a particular disease. These monogenic (single gene) mutations relate to rare conditions, such as cystic fibrosis or sickle cell disease, in which the presence of a particular faulty gene has been identified as the sole or predominant cause of the disorder, and patients with positive tests are counselled accordingly.
In contrast polygenic risk scores, as the name suggests, look at thousands of genetic variants across many genes that make up a person’s genome to estimate an individual’s risk of developing a particular disease. But most common chronic diseases will also have multiple social, environmental and lifestyle causes, that is, the genetic component may be a minor contributor to overall risk.

The potential for inequities in the use of PRS arises because their development requires large amounts of genetic data and, like AI, these data sources tend to be unrepresentative of the whole population in which they will be used. In particular, the major datasets upon which PRS are based are drawn from populations which are overwhelmingly European in ancestry, which may affect their clinical utility for people with other ancestries.

Without public and health professionals’ understanding of the multifaceted causes of common chronic diseases, PRS are also vulnerable to misinterpretation. Improper risk information may result in physical or financial harm to people receiving it, caused by unnecessary lifestyle or clinical interventions as well as unwarranted effects on mental health such as anxiety or depression.

At the extreme, the ethical and equity issues raised by the blanket use of PRS across a healthy population may have negative impacts in society. If, for example, the genetic information provided by PRS is wrongly interpreted as deterministic, it may be used to discriminate against specific groups with high scores in terms of jobs, employment and access to insurance and mortgages – a form of ‘genetic discrimination’.

To anticipate these challenges and counter them, we decided to focus on PRS within the wider field of medical devices based on genomics. Findings and recommendations are presented in section 8.

**Further filters**

Within the three types of medical device, we applied further criteria for review. We selected those devices for closer scrutiny where there was a plausible scientific mechanism for the bias leading to an adverse clinical impact on health or healthcare. If the scale of the bias had no potential or actual clinical significance for any population group, then it was not considered a priority for review.

Our terms of reference also limited our focus to considerations of bias associated with medical devices. Essentially, we reviewed evidence on the NHS equity components mentioned earlier related to medical devices causing biased selection of patients or biased performance. The separate equity components of inequities in geographic, economic and cultural access to medical devices or services were not within our remit, and draw on a completely different evidence base. They did, however, come up repeatedly in conversations with stakeholders and are flagged in our horizon scanning (section 9).
The perspective of patients

In reviewing the evidence on these three types of device, we believe it is important to keep the focus on people, not just devices. Throughout the report, therefore, we consider the findings from the perspective of patients encountering various medical devices during their journey through the health system. Case studies or scenarios trace what could happen to patients if there is bias related to the medical devices when decisions about their care are being made. All three sets of recommendations for the selected devices therefore start with actions to protect the public and patients.

Box 2: how AI can discriminate through racial profiling

In a scandal in the Netherlands which brought down the government, many parents and caregivers were falsely accused by the tax authorities of child benefit fraud. At the heart of the scandal was racial profiling using AI.

As part of a tough approach to the risk of fraud, in 2013 an algorithmic decision-making system was adopted for fraud detection using a ‘risk classification model’, which gave people with non-Dutch nationality a higher risk score. This meant the algorithm was programmed to connect being foreign with criminality. If the system selected people for investigation their benefit payments were suspended.

As a result of this system, the tax authorities falsely accused tens of thousands of parents and caregivers from mostly low-income families of fraud, with people from ethnic minorities disproportionately impacted. Thousands of families were forced to pay back benefits for minor discrepancies such as a missing signature. People were even driven into bankruptcy.

In 2020, Tendayi Achiume, then UN special rapporteur on contemporary forms of racism, racial discrimination, xenophobia and related intolerance, said that as states increasingly use digital technologies to calculate risk, greater scrutiny of their potential to have a disproportionate impact on racial or ethnic minorities must be a priority.
6. Potential ethnic and other unfair biases in optical medical devices

Our first focus was on devices that detect underlying pathology by taking non-invasive measurements through the skin with light or other mechanisms, which we term optical medical devices.

Non-invasive, light-emitting technologies have revolutionised medicine by allowing the estimation of levels of a molecule or biophysical process within the body without the need for an invasive test such as a blood sample.

In addition, some light emitting devices can provide continuous monitoring of a molecule, whereas many invasive tests can only be performed intermittently, making optical devices useful in clinically unstable patients. However, any device that relies on the emission and detection of light signals is prone to error. This chapter reviews the latest evidence on the effects of skin tone on the accuracy of light emitting medical devices.

First, we take pulse oximetry as a special case requiring an in-depth review and recommendations for immediate mitigation of bias. We then consider how to prevent unfair bias in optical devices longer-term.

**Pulse oximeters**

Oxygen remains the most widely used therapy in the NHS today in homes, ambulances and hospitals. Like any other therapy, the effect of oxygen needs to be carefully monitored, and this is usually achieved using pulse oximetry.

A pulse oximeter is a non-invasive medical device used to measure the amount of oxygen in arterial blood. It can detect a lack of oxygen in the blood, which is known as hypoxaemia. The value a pulse oximeter produces is referred to as the peripheral arterial oxygen saturation ($\text{SpO}_2$), which is an estimation of the true arterial oxygen saturation ($\text{SaO}_2$). $\text{SaO}_2$ can only be measured by taking a sample of arterial blood and analysing it in a blood gas machine. This test is invasive and painful and can only be carried out by specialists, while a pulse oximeter avoids the need for blood to be taken.
Pulse oximeters are usually clipped on to a finger like a peg (Figure 4) with the fingertip between the two arms of the clip, although other areas of the body can be used, such as the earlobe. Light of two wavelengths (visible red (9660nm) and near infrared (940nm)) is emitted from LEDs in one arm of the clip. The light passes through the finger to sensors on the other arm that detect light and measure how much comes through the finger.

Figure 4: A battery-operated fingertip pulse oximeter

As pulse oximetry relies on light to determine the level of oxygen in blood, the technology can be affected by several factors, including skin pigmentation, nail polish, motion, poor peripheral perfusion, fake tan, henna, tattoos and sickle cell disease. It has been known since 1992 that performance was poorer in patients with darker skin tone, but it is only in recent studies that the potential health impact has been recognised.

Is there evidence of poorer performance for patients with darker skin tones?

A range of studies have been carried out on population groups predominantly in the US, UK, Canada and Europe. From a review of the evidence carried out for this review by Professor Daniel Martin we conclude that there is extensive evidence of poorer performance of pulse oximeters for patients with darker skin tones. Larger studies with a broader diversity of participants tended to report significantly greater bias and less precision in non-White and other participants with darker skin tones. The evidence shows that:
• in people with darker skin tones, pulse oximeters over-estimate true oxygen levels
• pulse oximetry over-estimation gets worse in patients with low (more dangerous) levels of oxygen saturation and is particularly marked for people with darker skin tones

But do these pulse oximeter inaccuracies affect the care patients with darker skin receive?

**Evidence of health impact**

There have been fewer studies of the health impact of the racial bias in readings, but the number has been slowly increasing since the pandemic. The studies currently come from the US and involve examining the differential detection of dangerously low blood oxygen levels in different racial or ethnic groups. These studies have found poorer or delayed access to more advanced care when the pulse oximeter fails to identify how low the oxygen levels are in some patients.

The term occult – or ‘hidden’ – hypoxaemia describes a situation where a patient with relatively normal pulse oximetry blood oxygen saturation readings is shown to be hypoxaemic when oxygenation is measured in an arterial blood sample (SaO\(_2\)). Typically, this was defined as an SaO\(_2\) of less than 88% (with a paired SpO\(_2\) of equal to or less than 92%). This has become a useful tool for highlighting the proportion of patients whose hypoxaemia would be missed if only pulse oximetry was performed.

In the studies reviewed, hidden hypoxaemia was consistently found to be more frequent in participants with darker skin tones. A large Veterans Health Administration study in the US showed Black patients were more likely than White patients to have hidden hypoxaemia: 15.6% of White patients compared with 19.6% of Black patients and 16.2% of Hispanic or Latino patients.

The conclusion from US retrospective observational database studies is that there were differences in the incidence of hidden hypoxaemia between ethnicities (not skin tone) because of pulse oximeters over-estimating SaO\(_2\), with a greater variability in oxygen saturation levels for a given SpO\(_2\) level in patients who self-identified as Black, followed by Hispanic, Asian and White.

This racial inequity was associated with harm that included delayed recognition of disease, denied or delayed treatment, worse organ function and death. From these studies the relationship between oxygenation overestimation and outcome cannot be said to be causative, but they point to a strong association.

An added inequity comes from the nature of the healthcare financing system in the US, where health insurance cover can make all the difference to whether the person with hidden hypoxaemia gets the care they need. Medicare reimbursement (the state scheme for paying for care of people in poverty) uses pulse oximeter measures as thresholds for approving payment of care. A reading of 88% or 89% qualifies a person for reimbursement for oxygen at home, but a reading of 90% does not. In real life, this represents a double inequity: people with darker skin tone may have to be sicker to
qualify for the same treatment as people with white skin tone, and the treatment they need may be unaffordable if they have to rely on Medicare rules that are stricter than for private health insurance cover.

There are no payment thresholds of this nature in the UK NHS, as services are free at the point of use. It is therefore unlikely that this particular inequity would arise, but there is still the potential for hidden hypoxaemia being more prevalent in patients with darker skin tones in the UK if, for example, clinical guidelines specify too high a pulse oximeter threshold for more intensive treatment. So far, we do not have empirical evidence from studies in the NHS of this differential performance affecting care. It is clearly plausible, however, that the observed poorer performance of pulse oximeters with darker skin tones translates into poorer access to services. We set out a reasoned case in figure 5 below for a patient pathway leading to worse health outcomes given the inherent bias in pulse oximeters.

**Patients’ perspectives**

COVID-19 pneumonia is a disease characterised by low blood oxygen levels, so it serves as a useful example of how hidden hypoxaemia can have devastating consequences for patients. During the COVID-19 pandemic pulse oximetry readings were one of the clinical factors which guided treatment interventions including hospitalisation, the use of supplemental oxygen and pharmacological therapies such as dexamethasone. Inaccuracy in these readings, in particular over-estimation of arterial oxygen levels, could therefore have resulted in the under-treatment of patients in whom this inaccuracy was greatest.

Throughout the clinical pathways for a patient with a condition that leads to low blood oxygen levels, such as COVID-19 pneumonia and sepsis, there are times when important decisions must be made. Healthcare teams need to know when a patient should call an ambulance, when they should be admitted to a hospital, when clinical management needs to be escalated to intensive care and when specific treatments should be started.

Figure 5 shows a typical pathway for a patient whose oxygen levels continue to fall below normal and who needs urgent attention. Each layer of the diagram shows how failing to identify hypoxaemia would lead to a patient receiving substandard treatment. The finding that hidden hypoxaemia is more likely in patients with darker skin tone suggests that inherent bias in pulse oximeters against darker skin tones could have adverse health impacts for these patients.

Ultimately, hidden hypoxaemia is likely to lead to under-estimation of the severity of a patient’s condition, delays or even withholding of potential life-saving interventions and a greater likelihood of them not surviving their acute illness.
Figure 5: A typical clinical pathway for a patient with an acute medical condition leading to low blood oxygen levels

What should be done to tackle racial bias in pulse oximetry?

The search for more equitable solutions is now taxing the minds of many organisations nationally and internationally. Both the MHRA in the UK and the FDA in the US have made racial bias in pulse oximeters a priority focus for systematic reviews of the evidence, primary research on accuracy by skin tone and consultations on new standards and guidance. Updating of EU and ISO standards for pulse oximeters is also underway.

We commend the programme of work on pulse oximetry that the MHRA has initiated over the past two years, summarised in Box 3. Our recommendations are intended to support and strengthen the impact of these efforts.
Box 3: MHRA initiatives to strengthen regulation and monitoring of pulse oximeters

The MHRA programme includes:54

- an ongoing scientific review of the potential for inaccuracies of pulse oximeters on different skin tones
- work with international collaborators on improving information and standards for these devices
- future medical device regulations which are under development and would strengthen requirements for manufacturers in line with technological progress and international best practice to deliver public and patient safety benefits, including periodic safety reports monitoring specific concerns with particular devices
- implementation of questions relating to representativeness of different intended user populations in medical device clinical investigation applications which the MHRA reviews, with this advice intending to be incorporated into guidance
- work to improve the Yellow Card reporting system and other resources for safety signal detection and review for medical devices. The MHRA uses a range of tools and approaches in medical device vigilance and there are wider improvements for capturing data on medical devices ongoing across the healthcare system which will improve data available for signal detection and assessment.

Several academic networks have also publicised the problem and called for action, including the independent NHS Race & Health Observatory,55 Federation of American Scientists56 and American Medical Association.57 Having weighed up the evidence and listened to stakeholders, including the perspectives of patients, we make three high-level recommendations for immediate mitigation of racial bias in pulse oximetry, intended to reinforce the serious efforts on many fronts that are already underway.

Challenge: immediate mitigation of pulse oximeter bias

Pulse oximeters are valuable medical devices in widespread use in the NHS and around the world, but there is evidence they do not perform as well with patients with darker skin tones and that this bias can adversely affect the treatment they receive. Immediate mitigation measures are needed to ensure existing devices can perform to a high standard for all patient groups to avoid serious inequities in health outcomes.
6. Potential ethnic and other unfair biases in optical medical devices

This review recommends that:

**Recommendation 1:**

Regulators, developers, manufacturers and healthcare professionals should take immediate mitigation actions to ensure existing pulse oximeter devices in the NHS can be used safely and equitably for all patient groups across the range of skin tones. This requires action on several fronts:

- the MHRA should strengthen its guidance for patients and caregivers using oximeters at home, and for healthcare professionals, on the accuracy and performance of pulse oximeters. This should include guidance on taking and interpreting readings from patients with different skin tones. Renewed efforts should be made to promote this guidance to health professionals throughout the NHS and to patients and the public.

- health professionals should advise patients who have been provided with a pulse oximeter to use at home to look at changes in readings rather than just a single reading, to identify when oxygen levels are going down and when they need to call for assistance. Patients should also be advised to look out for other worrying symptoms such as shortness of breath, cold hands and feet, chest pain and fast heart rate.

- clinical guideline developers and health technology assessment (HTA) agencies such as the National Institute for Health and Care Excellence (NICE) should produce guidance on the use of pulse oximeters emphasising the variable accuracy of $\text{SpO}_2$ readings in patients with darker skin tones, and recommend the monitoring of trends rather than setting absolute thresholds for action.

- Health Education England (part of NHS England) and the respective agencies in the devolved nations should educate clinicians about how the technology of pulse oximeters works, and advise that treatment should not be withheld or given on the basis of absolute thresholds alone. Clinicians should be trained to monitor trends rather than absolute thresholds for action based on $\text{SpO}_2$ in patients with darker skin tone, and understand the variable accuracy of $\text{SpO}_2$ levels.

- manufacturers of pulse oximeters must update their instructions for use (IFU) to inform patients and clinicians about whether the device is ISO compliant, the limitations of their model of pulse oximetry, any contra-indications, and its differential accuracy in patients with different skin pigmentation.

- the MHRA should issue updated guidance to developers and manufacturers on the need to make the performance of their device across subgroups with different skin tones transparent.
Challenge: standard setting and testing

One of the main reasons for the poorer performance of pulse oximeters for patients with darker skin tones is that they have tended to be tested and calibrated on light-skinned individuals, whose readings are then taken as the norm. The international standards that new pulse oximeters models must meet to be approved as medical devices do not require developers to demonstrate appropriate testing and accuracy of devices across the range of skin tones.

This review recommends that:

**Recommendation 2:**

The MHRA and approved bodies for medical devices\(^{58}\) should strengthen the standards for approval of new pulse oximeter devices to include sufficient clinical data to demonstrate accuracy overall and in groups with darker skin tones. Greater population representativeness in testing and calibration of devices should be stipulated. The approach should include:

- the MHRA and UK approved bodies following the US FDA in requiring manufacturers to obtain $\text{SpO}_2$ validity data from a diverse subject pool with a) a large number of participants, b) a diverse range of skin tones, and c) a clinically relevant range of oxygenation levels

- manufacturers and research funding bodies commissioning studies that include the population on which the device will be used, subjects with a diverse range of skin pigmentations and critically unwell subjects with poor perfusion. Validation of devices should be conducted in the intended use population and setting, such as at home or in an ICU

- manufacturers of medical grade pulse oximeters being required to comply with BS EN ISO 80601-2-61:2019 (medical electrical equipment – particular requirements for basic safety and performance of pulse oximeter equipment) to gain market approval

- healthcare equity impact assessments being essential requirements for developing or supplying pulse oximeters in the UK, to identify whether mitigating actions are needed to ensure they are fit for purpose for all racial and ethnic groups, and people of varying skin tones. Making these assessments an essential requirement is in line with technological progress and international best practice

Challenge: designing better oximeters

Although existing pulse oximeters generally work well, no current device appears to be immune from measurement error with respect to skin tone. In the long run, the challenge for researchers and device developers is to design smarter devices for measuring blood oxygen saturation that are equally effective with any skin tone.
This review recommends that:

**Recommendation 3:**

Innovators, researchers and manufacturers should cooperate with public and patient participants to design better, smarter oximeters using innovative technologies to produce devices that are not biased by skin tone. This could include:

- developing enhanced algorithms for oximeter device software to address measurement bias
- exploring the use of multi-wavelength systems, which measure and correct for skin pigmentation, to replace conventional two-wavelength oximeters

**Preventing bias in other optical devices**

Beyond the specific case of pulse oximeters, we broadened our inquiries to look at other medical devices that take measurements through a patient’s skin using light or related technologies and for which there were scientifically plausible mechanisms for results varying by skin tone. We summarise the evidence here from exemplars of different types of optical device, to illustrate the equity lens that needs to be applied to the research results.59

**Near infrared spectroscopy**

Near infrared spectroscopy (NIRS) is a non-invasive technology used to make measurements – typically of oxygen – in living tissue. NIR light can penetrate deeper into the skin and the structures below than visible red light and is most often used during brain and heart surgery. In contrast to the bias seen in pulse oximetry, NIRS readings tend to underestimate tissue oxygenation in participants with darker skin tones.60 The reasons for this difference were not evident from the published literature, but two studies provided evidence that if corrective factors were applied to the algorithms used in NIRS it was possible to overcome the errors that occurred as a result of skin tone.61, 62 However, it is clear that:

- dark skin tone may affect the ability to achieve high quality NIRS readings
- NIRS tends to underestimate true tissue oxygenation in people with dark skin tones63

This could lead to the opposite scenario to pulse oximetry, with unnecessary treatment to improve the oxygen values derived from the spectroscopy, when brain oxygenation is normal. The ramifications of this are unclear and have not been investigated.64
Transcutaneous bilirubinometers

Transcutaneous bilirubinometers are used widely to test newborn babies under NHS care for jaundice. Neonatal jaundice is caused by elevated serum bilirubin, manifesting as a yellowish skin discolouration, and is one of the most common diagnoses immediately after birth. Continuously high bilirubin levels can be toxic for the development of an infant’s central nervous system and lead to behavioural and neurological impairments. Screening for neonatal hyperbilirubinemia is therefore crucial because of the high prevalence and associated risk.

The gold standard screening for neonatal jaundice is total serum bilirubin (TSB) measurement. However, this technique is time-consuming and invasive as a blood test is required. A non-invasive device, the transcutaneous bilirubinometer, measures transcutaneous bilirubin (TcB) and is based on optical spectroscopy, which relates the amount of light absorption by bilirubin to the concentration of bilirubin in the skin. It is more suitable for newborn babies as it is non-invasive and timely. It significantly reduces the number of blood samples taken, reducing the workload of clinical and laboratory staff, waiting times and anxiety for families.

A rapid appraisal commissioned by this review identified 25 studies which examined the effectiveness of bilirubinometers in measuring TcB compared with TSB in different ethnic groups. The evidence suggested that in infants with darker skin tone there is an overestimation of TSB with TcB, which could lead to needless follow-up blood tests which are invasive, prolong hospital visits, increase parental stress and interrupt mother-infant bonding. In community settings where serum bilirubin measurements are unavailable and TcBs are the only method of monitoring, these overestimates may lead to unnecessary hospital visits.

Newer devices are being developed which aim for more sophisticated and tailored measurement of bilirubin to maintain high accuracy irrespective of skin tone.

Dermatology devices

Devices employed in dermatology and known to be influenced by a patient’s skin tone are often adjusted to take account of it. However, some that are or might be influenced by skin tone may not be recognised as such by many medical practitioners and patients. In these cases there is a risk that darker skinned patients might receive poorer care. Two examples are:

Ultraviolet radiation phototherapy

Ultraviolet radiation (UV) phototherapy is used for treating several skin conditions. UV phototherapy is a good example of a medical device that takes a patient’s skin tone into account when setting the correct dose.

Skin conditions where phototherapy may be used include psoriasis, eczema, cutaneous T-cell lymphoma such as mycosis fungoides, vitiligo, lichen planus, morphea, polymorphous light eruption and graft-versus-host disease. Phototherapy is mainly administered in hospital dermatology departments, where the doses of UV are usually calculated by the UV radiation phototherapy unit and the administering
of radiation doses overseen and documented by nursing staff. This is supported by regular monitoring of the UV radiation output from the machines by medical physics personnel.\textsuperscript{73}

However, following training by phototherapy nurses, hospital supervised self-administration of phototherapy can be undertaken in the patient’s home in some regions for certain people who live in remote areas.\textsuperscript{74, 75}

Melanin pigment in skin protects against the UV radiation in sunshine, but also against UV from phototherapy lamps that are used to treat skin disease. This generally means that lighter skinned patients require lower UV radiation so they do not burn. Darker skinned patients usually require higher UV doses so that adequate amounts penetrate the skin. Guidelines from organisations such as the British Association of Dermatologists and British Photodermatology Group advise that testing for the dose at which the patient would burn (such as minimal erythema dose (MED) for UVB and minimal phototoxic dose (MPD) for the combined drug and UV therapy PUVA) is conducted before treatment to ascertain a safe starting dose.\textsuperscript{76, 77}

It is well recognised that UV responses differ according to skin tone, and dermatologists control for this by individualising the treatment according to the patient’s skin tone and susceptibility to burning.

\textbf{Dermoscopy for identifying skin cancers}

A dermoscope is a non-invasive tool that can help identify skin cancers, improve diagnostic accuracy and minimise unnecessary biopsies. Doctors who use dermoscopy need to be trained in recognising skin disorders and lesions in darker skinned people (as well as in lighter skinned individuals) because it is recognised that the clinical signs may differ according to skin tone.\textsuperscript{78, 79}

However, in recent years several studies have identified a lack of photographs in textbooks and educational resources of skin disease and skin lesions affecting darker skinned individuals.\textsuperscript{80, 81, 82, 83} A 2021 review also found a dearth of darker skinned populations in clinical and research studies.\textsuperscript{84} With machine learning algorithms being developed to detect malignant melanoma there is added concern that the training sets for these algorithms contain images of lesions predominantly from fair-skinned individuals.\textsuperscript{85}

This concern is reinforced by a systematic review of the characteristics of publicly available skin cancer datasets, which found that participant ethnicity data were available for only 1.3% and skin tone data for only 2.1% of images from a total of over 100,000 skin legon images.\textsuperscript{86}

Organisations such as the British Association of Dermatologists are now addressing the lack of photographs in educational resources regarding skin disease and lesions affecting darker skinned people, promoting material to dermatologists and other doctors as well as the public.\textsuperscript{87, 88}
The patients’ perspective on skin diseases

Only limited data were available to determine whether there is racial bias in the technologies used to assess skin lesions. However, there are certainly concerns that diagnosis may be delayed or negatively affected when using dermoscopes and telemedicine technologies for people with darker skin tones. Perhaps the greatest concern is the potential for AI-enabled devices that have been trained on datasets using patients with lighter skin tones to make diagnostic errors in those with darker skin tones.

Much of the literature alludes to potential harm rather than highlighting actual harm. The scenario in figure 6 shows a hypothetical patient journey from the moment a patient notices a skin lesion to when they receive the appropriate treatment. It highlights the potential delays and diagnostic difficulties if there is racial bias in the technologies being used to aid the diagnosis.

Figure 6: A possible clinical pathway for a patient from noticing a skin lesion to receiving treatment.

Recommendations for preventing racial bias in optical devices

The following recommendations are focused on medical devices that take non-invasive measurements through a patient’s skin with light or related technologies and for which there are scientifically plausible mechanisms for performance varying by skin tone. From the evidence reviewed, we consider these devices to have considerable potential for racial bias that may lead to patient harm if it is not identified and addressed.

In the UK, the MHRA already has an extensive programme to strengthen capacity in its public protection role, in response to a recommendation in the Cumberlege report. Our recommendations support and promote the MHRA’s work.

Taking an optical device lifecycle approach, our recommendations cover greater recognition of the problem, the need for better source data, better tools, higher standards and monitoring and more knowledgeable staff for clinical use of optical devices in the interests of all patients.

Challenge: better recognition of the problem

There are hundreds of optical devices, particularly in dermatology, in use in the NHS which we know or have scientific grounds for suspecting have varying performance by skin tone. Some of this variation may be so small as to be harmless or has already been accounted for and appropriate adjustments made to the outputs.

What we do not know, because the research question has not been posed in any systematic way beyond pulse oximeters, is which ones exhibit racial bias to such an extent that they disadvantage or harm the health of patients with darker skin tones. To inform future research and development, an inventory of optical devices in common use that have high potential for racial bias is needed.

This review recommends that:

**Recommendation 4:**

The professional practice bodies in the UK, such as the royal colleges, should convene a task group of clinicians from relevant disciplines, medical physicists, public and patient participants, developers and evaluators to carry out an equity audit of optical devices in common use in the NHS, starting with dermatological devices, to identify those at particular risk of racial bias with potential for harm, that should be given priority for further investigation and action.

Challenge: more diverse source data and tools

Some optical devices may perform less well for darker skin tone patients because the source data used during their development contains images predominantly from people of light skin tones. Imaging databanks for skin cancer diagnostic devices
are prominent examples of this deficiency and could lead to more misdiagnosis of skin cancers in patients with darker skin tones. The lack of diversity in datasets can continue into the testing phase.

Even when evaluators attempt to test performance with people from a range of skin tones, the tools at their disposal or the ones that they build into the devices are often inadequate for measuring skin tone.

This review recommends that:

**Recommendation 5:**
Renewed efforts should be made to increase skin tone diversity in medical imaging databanks used for developing and testing optical devices for dermatology, including in clinical trials, and to improve the tools for measuring skin tone incorporated into optical devices. This will require a concerted effort on several fronts including:

- encouraging links between imaging databank compilers, professional bodies, optical device developers and clinicians to develop and improve accessibility of imaging data resources that reflect skin tone diversity within the population, for example, in databanks for skin cancer diagnosis
- the MHRA providing strengthened guidance to developers and manufacturers on improving skin tone diversity in testing and development of prioritised optical devices. The MHRA is already working towards such guidance as part of its programme on pulse oximeters
- research funders supporting additional incentives and patient-centred approaches to address logistical, financial and cultural barriers which limit participation of ethnic minority groups in clinical studies of optical devices
- researchers and dermatologists developing more accurate methods for measuring and classifying skin tone which are objective, reproducible, affordable and user-friendly. Current practice of using uncertain descriptors of ancestry, ethnicity or race to define patients with dark skin tone is ambiguous and problematic. In its discussions on updating standards, the MHRA is examining which measures would be most appropriate, with the aim of agreeing a consensus. This work is to be commended

**Challenge: better monitoring and safety signals**
Once optical devices are approved and put into use in the NHS, it is often difficult to monitor differential performance by skin tone, or to pick up safety signals that would warn of harm.
Manufacturers do not usually generate evidence on efficacy or suboptimal performance, or make this evidence publicly available. NHS procurement does not promote minimum standards for equity in the pre-qualification stage and pre-purchase validation checks.

It is important to monitor the performance of optical devices once in use and pick up any adverse effects, including by skin diversity. It is unlikely, however, that a traditional reporting system would have identified the issue of racial bias in optical devices such as pulse oximeters causing harm. While capturing ethnicity information in reports may help detect inequities in safety, this depends on the reporter identifying the issue in the first place.

This review recommends that:

**Recommendation 6:**

Once in use, optical devices should be monitored and audited in real-world conditions to evaluate safety performance overall and by skin diversity. This will ensure any adverse outcomes in certain populations are identified early and mitigations implemented. This requires a whole-system approach and should include:

- commitment from manufacturers at the pre-qualification stage to fund and facilitate the establishment of registries for collecting data across all population groups on patient demographic characteristics, use and patient outcomes following deployment of the technology
- HTA agencies (NICE, Scottish Health Technologies Group, Health Technology Wales) being provided with access to post-deployment monitoring and adverse effects data as part of their assessments of optical devices. These data should be considered alongside the wider evidence when determining the value of the optical device for NHS use
- NHS Supply Chain, National Services Scotland, Shared Services Partnership, Procurement and Logistics Service and other contracting authorities including a minimum standard of device performance across subgroups of the target population which will make transparent any equity impacts as part of the pre-qualification stage when establishing national framework agreements. Manufacturers need to declare whether they have considered minimum standards for equity
- DHSC and the devolved administrations updating the national pre-acquisition questionnaire (PAQ) used by NHS trust electrical biomedical engineering (EBME) teams when buying medical equipment to include a minimum designated standard for equity as part of the pre-purchase validation checks
• the approved body conducting regular surveillance audits of prioritised optical devices. The audits should include data submissions from the manufacturer and the Medical Device Safety Officer Network/Incidents and Alerts Safety Officer Network (representatives from NHS trusts in charge of reporting on safety), and should include data from the MHRA Yellow Card scheme for reporting adverse incidents and Learning From Patient Safety Events (LFPSE) reporting. These audits should include an evaluation of differential safety by ethnic group.

• the continued strengthening of the MHRA’s vigilance role, as specified in the Cumberlege report’s recommendation 6, which called for substantial improvements in adverse event reporting and medical device regulation, with an emphasis on patient engagement and outcomes.91

• better routine capturing of ethnicity data in electronic healthcare records, alongside better collection and collation of data on medical devices in use. This would enable the MHRA to conduct more rapid studies to build the evidence when a hypothesis about potential inequity in an optical device is made.

**Box 4: improving data on the use of medical devices**

There is substantial work being undertaken to improve the capture of data on use of medical devices.

The £12 million Scan4Safety project, led by the DHSC, is running in six acute NHS hospitals in England. It aims to help staff quickly and easily track each patient through their hospital journey.92

From the unique barcodes on wristbands patients receive when they enter hospital to the barcodes used to record their medication and the equipment used in their treatment, each code can be scanned to show which member of staff administered each treatment, at what time and where. The six sites are intended to demonstrate to the NHS how techniques used in industries such as aviation can improve efficiency and safety and release staff time for patient care.

The MHRA has been developing the idea of unique device identification (UDI). The government is supporting the idea of manufacturers assigning UDIs before applying to approved bodies for conformity assessment for a limited range of devices such as certain implants where it believes the traceability benefits for these high-risk devices are proportionate to the work involved.93

The MHRA evaluates a variety of data sources including electronic health records and the Clinical Practice Research Datalink (CPRD), which connects anonymised patient data from a network of GP practices across the UK to support real-world research.
The MHRA is examining whether the Yellow Card scheme for reporting adverse events could be linked to electronic health records. It believes this could significantly improve the collection of equity data in patient treatment and outcomes.

**Challenge: strengthening clinical education and training**

Optimising treatment and outcomes for individual patients depends on accurate assessment and diagnosis, for which knowledge of the signs and symptoms across skin tones is essential. The education, training and CPD of healthcare professionals need to be expanded to equip them to be aware of, and deal with, health equity issues arising in the use of these optical devices. Clinicians need to be trained to identify potential sources of bias in a similar way to how they are trained to recognise potential safeguarding issues.

*This review recommends that:*

**Recommendation 7:**

A review should be conducted by the relevant academic bodies of how medical education and CPD requirements for health professionals currently cover equity issues arising in the use of medical devices generally and skin diversity issues in particular, with appropriate training materials developed in response. This should include:

- undergraduate and postgraduate medical and allied health professions training including teaching clinicians about clinically relevant conditions where disease presentation differs between White and ethnic minority patients
- clinicians being made aware that when using dermoscopy or other medical devices to examine skin lesions, clinical signs may differ according to skin tone, and their training should include images of skin lesions in all skin tones
- clinicians receiving training in identifying potential sources of bias in medical devices, and in how to report adverse events to the MHRA
- where new devices are introduced into clinical practice, organisations and clinicians using the new devices ensuring there is sufficient training to acquire skills and competencies before the device is used
7. Preventing bias in AI-enabled medical devices

Historically a medical device was an inert piece of equipment manipulated by skilled operators, like the forceps in the hands of an obstetrician or a stent guided into place by a cardiologist. Today, however, healthcare is data driven. Most modern medical devices and technologies depend on the acquisition and analysis of real time data on individuals or populations.

These data streams are orders of magnitude larger and more complex than datasets that can be handled by any individual, so many of them come with AI or Machine Learning (ML) based algorithms.

AI is a computer programme with logic and rules that perform tasks usually associated with human-level decision-making. Machine learning is a subset of AI which gives a computer the ability to learn without being explicitly programmed. Machine learning algorithms optimise their performance to achieve a goal by training on data, and then making decisions based on situations it has already encountered and analysed, such as interpreting an image after being trained on large numbers of images.

Fully automated AI systems can operate without human intervention, although there may well be human checks such as a radiologist examining a scan identified as showing disease by an automated system. There are also hybrid systems combining automated and human activity, such as clinical decision support tools.

A significant risk with AI in medicine is the scope for biased outputs that undermine the principle of fair healthcare for all.

AI is everywhere in healthcare, and AI and other software can be regarded as medical devices. Although the use of AI and ML in medical devices and clinical care is in its infancy, the scope and coverage of digitally enabled devices is expanding exponentially. Newer imaging scanners that patients will be familiar with – whether they be ultra-sound heart scanners, retinal scanners or CT and MRI machines – now come with sophisticated AI software to assist in image interpretation.

Other specialties have now embraced AI-enabled devices, such as dermoscopes in dermatology to capture and help interpret images of skin lesions for the diagnosis of cancer. Many asthma specialists encourage their patients to use smart – AI-enabled – inhalers to assist in tailoring drug dosage and to give feedback on inhaling technique.
to aid adherence. Surgeons are increasingly using robotic devices to undertake precision dissection of tumours in vivo to spare healthy tissue, while ‘nanoparticle’ precision medicine will eventually be enabled by AI.\textsuperscript{96}

Alongside these uses by frontline clinicians, and less visible to patients, healthcare professionals and service managers now have sophisticated algorithms to interpret vast numbers of patients’ electronic health records (EHRs) to support work such as improving services or improving public health through earlier intervention to reduce illness.

**The challenges facing AI in healthcare**

There are important consequences for fairness when the device performs less well for certain population groups. For example, AI algorithms in many dermoscopes may not cater as well for non-White skin. The consequences could include increased false negative error rates for skin cancer detection and delayed treatment for patients from some ethnic groups.\textsuperscript{97}

The pandemic has highlighted the challenges of delivering fair outcomes when using AI algorithms to interpret healthcare records. COVID-19 hit some ethnic minority communities disproportionately hard, and some key data for targeting public health responses were more sparse or missing for certain non-White groups when compared with the majority population. If these data are then used to model future pandemics and other disease patterns, biased and erroneous predictions could be made which could undermine planning for future pandemics and lead to harm by misallocating resources.\textsuperscript{98}

The pandemic also taught us how using AI-enabled digital technology to support virtual care perpetuated some racial, ethnic and socio-economic inequities, because marginalised communities tended to have less access to digital devices and be less likely to have the skills to use them.\textsuperscript{99}

A review of these unfair biases and inequities was undertaken for this panel by the Alan Turing Institute. One of the most significant findings to emerge was that it is only possible to fully understand AI inequities by taking a whole-system and lifecycle perspective, that is, by understanding how the device has been developed, tested, deployed and used, and how its use impacts on health outcomes positively or negatively\textsuperscript{100} (see figure 3, section 4).

Rather than attempt to exhaustively unpack every dimension of these challenges, we are highlighting the most important problems relating to equity and AI-enabled devices and recommending how they could be addressed.

The challenges fall into five broad categories:\textsuperscript{101}

- problem selection – how health problems are selected and prioritised for AI-related development
- data collection and reporting – how data are selected for use in developing and testing a device
• outcome definition – how outcomes are defined and prioritised in the healthcare system
• algorithm development – how the underlying AI algorithms driving the device’s functionality are developed and tested
• post-deployment – how the device’s impacts are monitored once in use

Examples of unfair biases

Unheard voices, unseen people

When AI is built around a ‘standard patient’, other patients can be harmed. The assumptions built into technology around a standard patient – typically White, male, relatively affluent and born in the UK – can cause harms such as when women are underdiagnosed for heart disease, or Asian people are underdiagnosed for glaucoma. The further an individual or group of patients is from the standard patient, the greater the risk that their needs will not be identified and met by an AI-enabled device.

For example, there is evidence that South Asian patients in the UK are often under-diagnosed for dementia, due to cultural perceptions, language barriers and lack of cultural accessibility. Some of the cognitive tests used (such as the abbreviated mental test score) fail to account for different cultural identities and backgrounds, even to the extent of testing knowledge about significant events in British history which a recent migrant may not know about.

In response to situations like this the NIHR set up the Devices for Dignity cooperative (D4D), bringing stakeholders together to co-design device solutions for patient problems. A recent example underlines the importance of hearing the voices of marginalised groups. CognoSpeak, a so-called digital doctor, was developed by a D4D group at the University of Sheffield. People with dementia (who are typically under-represented in user evaluations), their families and healthcare professionals were intimately involved in developing the questions the device uses to assess cognition (thinking) and speech analysis to detect early impairment of cognition.

When the pandemic arrived, the team ran online meetings with patient and public involvement (PPI) collaborators. PPI means involving people in all aspects of the research process as partners rather than simply as research participants. Social media helped the research team build new connections with ethnic community groups. This allowed them to better understand:

• the experiences of people from ethnic minority and disadvantaged communities of the existing assessment process for dementia
• issues of sensitivity and taboo around dementia in different ethnic groups
• perspectives on technology development, AI, data ownership and data sharing in these groups
• preferences for the visual appearance and voice of the digital doctor so that future users will be able to choose who they would feel most comfortable interacting with
• culturally sensitive adjustments needed to the phrasing of the questions

Taken together these improvements should ensure this digital doctor works equally well for everybody.

Furthermore, digital health innovation must not be driven solely by commercial interests at the expense of patient needs. There is a key role for government and public funding bodies such as NIHR, Wellcome and Medical Research Council (MRC) in funding needs-based innovation focused on improving health for ethnic minority groups.\textsuperscript{110}

**Inadequate and unrepresentative data used for development**

There is extensive evidence of sampling, selection and representation bias in data used to train AI models. For example, numerous algorithms used to diagnose skin disorders and skin cancer have turned out to be less accurate when used on people with darker skin tones, largely because they were calibrated with unrepresentative data.\textsuperscript{111,112} This lower accuracy could have delayed the diagnosis of a serious condition in those with darker skin, potentially undermining treatment.

In contrast, a US study of a machine-learning algorithm showed how using more diverse data to train a machine involved in analysing x-rays improved patient outcomes among African Americans with knee pain.\textsuperscript{113}

This problem is not unique to research and development in AI. Evidence for the more systemic origins of the under-representation in clinical research of racial and ethnic minority groups has been offered by the NHS, along with possible solutions.\textsuperscript{114}

**Bias in identifying and defining predictors and outcomes**

Box 5 gives an example from the US of how bias against Black and low-income people can be introduced into algorithms at the stage of identifying and defining the predictor and outcome variables.

---

**Box 5: how potential bias gets introduced into algorithms: the case of opioid misuse**

In response to the opioid epidemic in the US, many pharmacies and health professionals are guided in their prescribing by the NarxScore algorithm. This draws on data from electronic health records and other sources, distilling the information into a three-digit NarxScore, designed to predict the patient’s risk of opioid misuse or overdose. Clinicians and pharmacists are told to check a patient’s score when prescribing opioids, to reduce misuse.
The complete list of variables in NarxCare’s proprietary algorithm and their weighting has not been published. However, certain variables that NarxCare may access could create biased predictions for many patients. For example, if race and factors that correlate with race, such as drug-related arrests from criminal justice data, were included, the structural inequities within the criminal justice system for minoritized patients could perpetuate inequity in opioid-prescribing decisions. Other variables might also affect patients from poor socio-economic backgrounds. For example, patients who pay for prescriptions in cash – a common payment method for people on low incomes in the US – are classified as higher risk.

There are concerns that the proxies used to calculate patient risk scores produce inflated scores for marginalised patients, including: women and racial minorities with complex, pain-related conditions; poor, uninsured, under-insured, and rural individuals; and patients with co-morbid disabilities or diseases, including substance use disorder and mental health conditions.\(^{115}\)

There are similar concerns about gender bias in predicting cardiovascular disease. The symptoms of acute coronary syndrome presented by women are different to those in men, so they may experience delays in getting the care they need. This delayed care may be picked up in training data for machine learning as an indicator of less severe illness in women than men. Bias in clinical practice is then fed into the AI system to generate further bias.\(^{116}\)

More subtly, outcomes may be subject to bias due to inappropriate correction or adjustment for race – a practice applied in the US in particular. Spirometers used to assess lung function and diagnose respiratory conditions have systemically misdiagnosed non-White patients by applying standards of healthy lung function that differ across racial categories. Its race-based correction erroneously assumes a 10 to 15% smaller lung capacity for Black patients and 4-6% smaller capacity for Asian patients compared with their White counterparts.

By correcting for the supposedly lower lung capacities of non-White patients, race-adjusted spirometry results can lead to both an underestimation of ventilatory defects – a major issue during the COVID-19 pandemic – and discriminatory treatment planning, which could steer resources away from non-White patients who need pulmonary rehabilitation and monitoring.\(^{117}\)

**Bias in how AI devices are developed and tested**

Applying a one-size-fits-all approach to building algorithms to diagnose and monitor diabetes could lead to different results by gender and ethnicity if haemoglobin A1c (HbA1c) levels are included, because haemoglobin levels vary along gender and ethnic lines.\(^{118,119,120}\) This highlights the importance of fusing AI knowledge with a broader appreciation of physiology.
More generally, developers of AI-driven applications for predicting outcomes from electronic health records must understand the clinical processes that shape the data as well as the biology. The data are often indirect measures, reflecting the patient’s interactions with the healthcare system as well as their health status. They encompass evolving clinical judgements and decisions about treatment and other unobservable clinical and administrative processes that influence the presence or absence of data. So analysing health records requires an awareness of the context in which they were generated. Without the context, data from health records are unsuitable for many research questions.

Contextual issues include clinical learning over time, the evolution of treatment in response to research, changes in treatment policies and levels of care. Equity issues include patients’ interactions with discriminatory institutional processes, biased clinical judgements about treatment pathways and implicit biases in the care environment.

**Monitoring AI devices in use**

There are many ways in which bias can be introduced in how devices are used, so once a technology is in the hands of NHS staff and patients the monitoring needs to be adapted to match the risks.

For example, a machine learning-based system may produce a prediction without making clear the prediction uncertainty, or when it has insufficient information to make the prediction. An AI decision support system may be unsafe if it predicts a low risk of a disease when some relevant data are missing – and ethnic minority and low-income groups are often missing from population datasets or have more ‘predictor’ variables missing. Without any information about the prediction confidence, a clinician may not have a clear idea of whether the prediction is trustworthy.

AI devices need to be designed and calibrated to take account of clinical impact, not just performance accuracy. A system which is set up to have high specificity – few false-positive results – may be impressive technically but it increases the risk that diagnoses just outside the treatment range are missed. This is where small biases can have a big impact, by making the difference between being treated and not being treated.

Conversely, a system which has high sensitivity – few false-negative results so hardly anyone gets missed – may lead to unnecessary treatments. As well as risking overloading services, there is again an opportunity for unfair bias creeping in through seriously ill people who need urgent treatment being crowded out by more marginal cases. Each AI device needs to be optimised appropriately for its task.

**The perspective of patients**

It is important to understand what such biases in AI-enabled medical devices mean from the perspective of patients. In box 6 we follow two hypothetical patients with glaucoma through their journey in the health system and how their outcomes may differ due to bias in the equipment they encounter. In the future, eye specialists
anticipate that the diagnosis of glaucoma will increasingly be guided by AI. Although this has the potential to improve the accuracy and efficiency of diagnosis, it is essential that these algorithms are built on inclusive data. The risks of embedding existing human bias within AI systems are high.

Unless an inclusive approach is taken to the representation of diversity (including ethnicity) within the data used for training and testing these systems, there is a considerable risk of building AI tools that only work for certain groups, and which exclude and cause harm to others.

**Box 6: building in bias – the glaucoma pathway**

Glaucoma is a common, chronic disease which can cause loss of vision and blindness. Its diagnosis and management is guided by a number of measurements such as eye pressure, retinal thickness and visual field, all of which rely on medical devices.

Rob, a 62-year-old White British man, visits a high street optometrist for an eye test. The pressure in his eye is measured and found to be high, so he is referred to a hospital eye clinic. The eye doctor who sees him there is concerned he may have glaucoma, and arranges for a high-resolution scan of his optic nerve and surrounding retina using an optical coherence tomography (OCT) scanner.

Automated software tools process the scan and help the doctor review it by separating and labelling the layers of the retina. The software also provides an indication of whether these measurements are abnormal, by comparing them with a reference database of measurements taken from people without eye disease.

The results show Rob’s measurements are abnormal, as layers of his retina are thinner than the reference database. He also has a visual field test which shows mild loss of peripheral vision. Rob’s OCT results and visual field results, taken with his history and examination, suggest to his doctor he may have glaucoma. He is therefore started on daily eye-drop treatment to lower his eye pressure. This lifelong treatment protects his vision, and he continues to have good sight for the rest of his life.

Aysha, a 57-year-old British Asian woman, is also referred to hospital eye services by her optometrist after having had a high intraocular pressure measurement on an eye test. She has an OCT scan like Rob. Aysha’s measurements appear normal compared with the reference database. Aysha also has a visual field test. Like many patients, she finds that test difficult to perform and her results are therefore inconclusive. She is not diagnosed with glaucoma.
A year later Aysha starts to notice she is missing things at the edge of her vision. On her next eye clinic appointment she has another OCT scan. Her retinal thickness is still within normal range. However, there is significant thinning compared with the year before. She finds it easier to do the visual field test this time, but unfortunately the result from this suggests she has lost a lot of peripheral vision. She is diagnosed with glaucoma and started on treatment. She experiences no further deterioration in vision but never recovers what was lost, and is no longer able to drive due to the damage to her peripheral vision.

Analysis

These two individuals have the same condition and receive the same tests but with very different outcomes. The issue here is not with the device itself but with the software which helps the clinician interpret those results.

The optic nerve and related structures can vary significantly between healthy people, and may be affected by a range of factors including ethnicity. The critical structure here – the retinal nerve fibre layer – is, on average, thicker in people of Asian than European ancestry. So different ethnic groups may have different normal ranges. In this case the scanner has only one reference database, from a European ancestry population.

The high pressure was affecting Rob and Aysha equally, causing 10% nerve loss. This damage brought Rob's measurements into the software's abnormal range so he was diagnosed and treated. In Aysha, this damage was not acted on because her measurements were still in the normal range according to the reference database.

These limitations may be recognised by manufacturers and regulators, and regulatory approval may specify that software should only be used for certain ethnic groups. However, once such tools are in the clinic they are often used by staff who are unaware of the limitations of the reference databases. Individuals who are not represented within the database are therefore at risk of harm. Developing more inclusive reference datasets are one part of the approach to reducing this risk.

Source: scenario prepared by Dr Peter Woodward-Court, Dr Trystan Macdonald, Professor Rupert Bourne, and Professor Alastair Denniston for the independent review, April 2023.

What are the solutions?

How do we reap the benefits of AI while preventing or minimising the harms? The potential to generate unfair biases and inequity through AI medical devices is being vigorously researched in fields such as computer science, medicine, public health and ethico-legal scholarship.
The MHRA is engaged in a Software and AI as a Medical Device Change Programme, to ensure device regulation is fit for purpose for AI and other software. The aims are to ensure a high degree of protection for patients and the public, strengthen the UK’s reputation as a home of responsible innovation for medical devices and to collaborate closely with key partners such as NICE and NHS England so that the rules are clear and easy to navigate.

Guiding principles for developing devices with machine learning (Table 1), developed jointly by the MHRA, Health Canada and the FDA, aim to help manufacturers and users avoid the perpetuation of inequities through a framework to identify, measure, manage and mitigate bias.

Table 1: Good Machine Learning Practice for Medical Device Development

<table>
<thead>
<tr>
<th>Guiding Principles</th>
<th>Good software engineering and security practices are implemented</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multi-disciplinary expertise is leveraged throughout the total product life cycle</td>
<td>Training data sets are independent of test sets</td>
</tr>
<tr>
<td>Clinical study participants and data sets are representative of the intended patient population</td>
<td>Model design is tailored to the available data and reflects the intended use of the device</td>
</tr>
<tr>
<td>Selected reference datasets are based upon best available methods</td>
<td>Testing demonstrates device performance during clinically relevant conditions</td>
</tr>
<tr>
<td>Focus is placed on the performance of the Human-AI team</td>
<td>Deployed models are monitored for performance and re-training risks are managed</td>
</tr>
<tr>
<td>Users are provided clear, essential information</td>
<td></td>
</tr>
</tbody>
</table>

In 2022 the Regulatory Horizons Council (RHC) reviewed the regulation of AI as a medical device and outlined how regulatory reform could protect patients from ineffective, unsafe and discriminatory devices while supporting innovation and accelerating the adoption of safe and equitable devices that improve care.

It recommended that key organisations such as NICE and the Care Quality Commission (CQC) scrutinise the use of AI devices and require evidence that the risks of poor generalisability and bias have been evaluated and mitigated.

The World Health Organization (WHO) has made recommendations around the ethics and governance of AI to ensure human rights are at the heart of its design, deployment and use.

The NHS AI Lab is working with NICE, the MHRA, Health Research Authority (HRA) and CQC to establish a multi-agency advisory service (MAAS) to give innovators and health and care providers a one-stop-shop for information and support on the regulation and evaluation of AI technologies. The NHS AI Lab has also set up an AI ethics initiative to support research and interventions that could strengthen the ethical adoption of AI.
NICE’s evidence standards framework for digital health technologies include the need to consider health and care inequalities and bias mitigation.\textsuperscript{132}

The Ada Lovelace Institute, which promotes the just and equitable distribution of the benefits of data and AI, has advocated the use of algorithmic impact assessments (AIAs) as a way for governments, public bodies and AI developers to understand the potential benefits and harms from AI systems.\textsuperscript{133} NHS England responded by piloting AIAs. The assessments aim to ensure that risks such as algorithm biases are addressed before a technology can access NHS data.\textsuperscript{134}

The Data Science for Health Equity community is just one example of numerous national and international science collaborations aimed at the equitable development and use of healthcare AI.\textsuperscript{135} The Alan Turing Institute Health Equity Interest Group connects researchers with public health, health and care professionals and the public to advance health equity by developing methodologies and digital tools to address existing inequalities and apply the latest innovations in data science and AI to healthcare.\textsuperscript{136}

Scientists are improving the transparency and rigour of AI research in healthcare with, for example, the formulation of the TREE framework,\textsuperscript{137} and a suite of reporting guidelines. These include CONSORT-AI (Consolidated Standards of Reporting Trials-AI), DECIDE-AI (Developmental and Exploratory Clinical Investigation of DEcision-support systems driven by AI) and QUADAS-AI (QUality Assessment tool for AI centered Diagnostic test Accuracy Studies).\textsuperscript{138, 139, 140} In addition, STANDING Together, an international consortium, is developing standards for AI datasets that promote diversity, inclusivity and generalisability.\textsuperscript{141}

We commend these important initiatives that recognise the emerging challenges of AI in healthcare and are working towards solutions. Our review focused on a specific area of this rich AI landscape – ensuring equity in AI-assisted medical devices in the NHS. We first identify eight challenges to ensuring equity. We then set out our recommendations for improvement.

The central aim of our recommendations is to enable the development of more equitable AI devices – what needs to happen in this rapidly evolving field to ensure future AI-assisted medical devices are fair and equitable in design, use and impact?

**Recommendations towards bias-free AI-assisted devices**

**Challenge: hearing and responding to the right voices and questions**

Patients are still seldom heard or engaged in defining the most pressing questions in improving outcomes from AI devices. Efforts to include these voices have often been tokenistic and have not supported people to participate in a co-design process through the device lifecycle.
Support is important to help people understand all the areas where the systems or clinical pathways into which a new device is inserted is prone to fail them or is susceptible to bias. Capturing the necessary diversity of views of patients and other stakeholders can be more difficult if the device development and deployment teams are themselves not diverse.

It is especially important that the patient perspective is available to influence the development of AI medical devices as AI is particularly sensitive with respect to public trust, to the potential impact of non-representative training data and the misalignment of training goals with those of users.

This review recommends that:

**Recommendation 8:**

AI-enabled device developers, and stakeholders including the NHS organisations that deploy the devices, should engage with diverse groups of patients, patient organisations and the public, and ensure they are supported to contribute to a co-design process for AI-enabled devices that takes account of the goals of equity, fairness and transparency throughout the product’s lifecycle.

Engagement frameworks from organisations such as NHS England can help hold developers and healthcare teams to account for ensuring that existing health inequities affecting racial, ethnic and socio-economic subgroups are mitigated in the care pathways in which the devices are used.

**Box 7: good practice in patient and public involvement in AI algorithm development**

InnerEye was a project in Cambridge to develop an AI algorithm to support radiotherapy planning in cancer treatment which incorporated patient and public involvement throughout the device’s lifecycle.

The Cambridge University Hospitals PPI Panel was involved in the preparation of early and later-phase funding applications for the project, as well as during the development of the device through a Q&A session and focus group discussions.

The panel emphasised the importance of explaining jargon and buzzwords, and felt that educating people about AI was essential to explaining how the device would be used to patients.

They also emphasised that clinicians need to clearly state that the algorithm will only be used as a tool to assist decision-making rather than replacing the judgment of clinicians. Panel members stressed that face-to-face appointments with clinicians are important to reduce any worries patients may have about AI.
The PPI panel raised questions around trust in AI. Is it reliable, who has access to the data, and is it secure? They highlighted the importance of clinicians being transparent if they are using AI in patient care, and in what way it is being delivered.

By building public and patient involvement into the design of this project, the patient voice influenced the development of the device, as well as the language used to describe it to patients and the public.

Sourced for the independent review with support from the CUH Public and Patient Involvement Panel.143

**Challenge: insufficient awareness and understanding of the issues affecting equity in AI development and deployment**

Even when the right voices are heard, there is a lack of understanding among the public, technologists, healthcare staff and all those involved in the medical device lifecycle of the potential for unfair biases in AI development and deployment and of the need to consider equity at every stage.

*This review recommends that:*

**Recommendation 9:**

The government should commission an online and offline academy to improve the understanding among all stakeholders of equity in AI-assisted medical devices. This academy could be established through the appropriate NHS agencies and should develop material for lay and professional stakeholders to promote better ways for developers and users of AI devices to address equity issues, including:

- ensuring undergraduate and postgraduate health professional training includes the potential for AI to undermine health equity, and how to identify and mitigate or remove unfair biases
- producing materials to help train computer scientists, AI experts and design specialists involved in developing medical devices about equity and systemic and social determinants of racism and discrimination in health
- ensuring that clinical guideline bodies identify how health professionals can collaborate with other stakeholders to identify and mitigate unfair biases that may arise in the development and deployment of AI-assisted devices
- encompassing an appreciation of AI within a whole-system and lifecycle perspective and understanding of the end-to-end deployment and potential for inequity
Challenge: the need for AI medical device development to be based on diverse datasets and population subgroups

During development, AI-assisted medical devices are often tested and validated on samples that do not represent the population in which the device will be deployed. The performance of the device in the under-represented groups is therefore not known, and neither these limits on performance nor the trade-off between effectiveness and equity are transparent to users.

A contributor to this problem is that developers do not have access to representative reference datasets. This is compounded by the fact that real world data itself reflects a variety of selection biases that are related to the way AI-assisted devices are deployed. Women, ethnic minority and socio-economically disadvantaged groups are among those under-represented in commonly used data sources. This problem affects datasets that are used across the AI lifecycle and has numerous causes, including:

- differential access to care
- poor data coding, such as for racial and ethnic categories
- more data missing on disadvantaged participants
- varying prevalence of comorbidities
- local or regional variations in data quality assurance
- lack of public understanding of why their data are needed or how they are used
- lack of public trust in how their data are used
- women, older people and those from ethnic minorities and more disadvantaged backgrounds less likely to be recruited to clinical trials

Inferences drawn from unrepresentative data will be misleading or limited. Data needs to be more representative and inclusive so that they can be used reliably for all parts of the population.

During development, AI devices need to be tested and validated with the key subgroups of the population in which they will be used. Regulators, commissioners, users and patients need to know whether a device has been tested in a relevant group and what its performance was in that group.

We support initiatives such as those by the Office for National Statistics (ONS), DHSC and NHS to improve the quality of public data, notably around ethnicity.
Box 8: how can we be more inclusive in our data?

The UK Statistics Authority guidelines on inclusivity in data recommend:\(^{150}\)

- creating an environment of trust and trustworthiness which encourages everyone to count and be counted
- taking a whole-system approach, working with others to improve data inclusiveness
- ensuring all groups are robustly captured in the data and reviewing practices regularly
- improving data infrastructure to enable robust and reliable disaggregation and analysis across the range of groups and populations
- creating new approaches to understanding experiences across the population
- standards should be reviewed at least every five years to reflect changing social norms and needs

This review recommends that:

**Recommendation 10:**

Researchers, developers and those deploying AI devices should ensure they are transparent about the diversity, completeness and accuracy of data through all stages of research and development. This includes the sociodemographic, racial and ethnic characteristics of the people participating in development, validation and monitoring of product performance. This should include:

- the government resourcing the MHRA to provide guidance on the assessment of biases which may have an impact on health equity in its evaluation of AI-assisted devices and the appropriate level of population detail needed to ensure adequate performance across subgroups
- encouraging the custodians of datasets to build trust with minoritized groups and taking steps with them to make their demographic data as complete and accurate as possible, subject to confidentiality and privacy
- developers, research funders, regulators and users of AI devices recognising the limitations of many commonly used datasets and seeking ones that are more diverse and complete. This may require a concerted effort to recruit and sample underrepresented individuals. We commend initiatives internationally and in the UK (such as the NIHR-led INCLUDE guidance) to encourage the development and use of more inclusive datasets. Data collection by public bodies must be properly resourced so that datasets are accurate and inclusive
dataset curators, developers, and regulators using consensus-driven tools, such as those by STANDING Together (see box 9) to describe the datasets that are used in developing, testing and monitoring

• regulators requiring manufacturers to report the diversity of data used to train algorithms

• regulators providing guidance that helps manufacturers enhance the curation and labelling of datasets by assessing bias, being transparent about limitations of the data, the device and the device evaluation, and how to mitigate or avoid performance biases

• regulators enforcing requirements for manufacturers to document and publicise differential limitations of device performance, and where necessary to place reasonable restrictions on intended use

• the Health Research Authority and medical ethics committees approving AI-enabled device research making sure they do not impose data minimisation constraints which could undermine dataset diversity or the evaluation of the equity in the outcomes of research

Box 9: standards for inclusive AI development in healthcare

STANDING Together is an international group of health professionals, technologists and patient representatives aiming to promote the development of AI healthcare technologies which benefit all patients by building representative datasets. Its draft recommendations for dataset standards supporting diversity, inclusivity and generalisability include:151

• dataset curators should document the contents, source and purpose of each dataset so data users can assess whether it meets their needs

• documentation should explain why this dataset was created, who created and funded it, who is intended to benefit, where the data come from and any purposes for which it should not be used

• documentation should describe how the curation team has considered the impact of their assumptions and preconceptions on biases, a summary of the populations in the dataset and an explanation of why and how groups were chosen and categorised. Any known missing groups should be highlighted and the reason for their absence explained
Challenge: systemic and institutional issues can bake in unfair biases

Even if issues around unrepresentative or bias in data are addressed, systemic and institutional biases are still likely to disadvantage some population groups. These baked-in biases include the lack of diversity in innovation teams, the way healthcare challenges are identified, prioritised and funded, how issues are analysed and how judgments are made about acceptable performance of AI devices.

Among the key regulations for healthcare AI is the MHRA’s classification of general medical devices. Class I is for low-risk items such as bandages, Classes IIa and IIb cover a range of medium risk devices from suture needles to ventilators, while Class III covers the highest-risk devices such as pacemakers. We believe that the growing awareness of the risks of patient harm through bias in AI justifies a more robust approach to the regulation and classification of AI-enabled devices.

This review recommends that:

Recommendation 11:
Stakeholders across the device lifecycle should work together to ensure that best practice guidance, assurance and governance processes are coordinated and followed in support of a clear focus on reducing bias, with end-to-end accountability. This should include:

- the MHRA adjusting its risk assessment of AI-assisted devices, so that all but the simplest and lowest risk technologies are categorised under Class IIa or higher, including a requirement for their algorithms to be suitable for independent evaluation, the use of a test of overall patient benefit that covers the risks of biased performance, and a requirement for manufacturers to publish performance audits with appropriate regularity which include an assessment of bias.

- supporting health professionals’ involvement early in the development and deployment of AI devices. We commend the use of ethical design checklists which may assist in the quality assurance of these processes.

- manufacturers adopting the MHRA’s Guiding Principles for Good Machine Learning Practice for Medical Device Development.

- all stakeholders supporting the MHRA Change Programme Roadmap, such as promoting the development of methodologies for the identification and elimination of bias and testing the robustness of algorithms to changing clinical inputs, populations and conditions.

- placing a duty on developers and manufacturers to participate in auditing of AI model performance to identify specific harms. These should be examined across subgroups of the population, monitoring for equity impacts rather than just unequal performance.
Challenge: ensuring regulation keeps pace with AI innovation and development

Excessively tight pre-market regulation of AI-assisted medical devices may stifle innovation, but systems for pre-market regulation for device safety are not matched by post-deployment monitoring for equitable health outcomes.

There is a lack of awareness and transparency of these post-deployment monitoring systems among key users and stakeholders. Direct-to-consumer devices – not included in this review – may be prone to the same sorts of biases as those afflicting regulated devices.

This review recommends that:

Recommendation 12:

• UK regulatory bodies should be provided with the long-term resources to develop agile and evolving guidance, including governance and assurance mechanisms, to assist innovators, businesses and data scientists to collaboratively integrate processes in the medical device lifecycle that reduce unfair biases, and their detection, without being cumbersome or blocking progress.

Challenge: the NHS needs to play a pivotal role in shaping and coordinating a systemwide approach to promoting equity in AI-assisted devices

The reach and influence of the NHS puts it in a unique position to support UK innovation in the development and deployment of equitable AI devices in healthcare, and prevent biased devices being adopted.

This review recommends that:

Recommendation 13:

The NHS should lead by example, drawing on its equity principles, influence and purchasing power, to influence the deployment of equitable AI-enabled medical devices in the health service. This should include:

• NHS England and the NHS in the devolved administrations including a minimum standard for equity as part of the pre-qualification stage when establishing national framework agreements for digital technology

• NHS England updating the digital technology assessment criteria (DTAC) used by health and social care teams when buying digital technology to recommend equity as part of the pre-purchase validation checks
• working with manufacturers and regulators to promote joint responsibility for safety monitoring and algorithm audits to ensure outcome fairness in the deployment of AI assisted devices. This will require support for the creation of the right data infrastructure and governance

**Challenge: research commissioners have an important role to play in promoting diversity and inclusion**

*This review recommends that:*

**Recommendation 14:**
Research commissioners should prioritise diversity and inclusion. The pursuit of equity should be a key driver of investment decisions and project prioritisation. This should incorporate the access of underrepresented groups to research funding and support, and inclusion of underrepresented groups in all stages of research development and appraisal. This should include:

• requiring that AI-related research proposals demonstrate consideration of equity in all aspects of the research cycle

• ensuring that independent research ethics committees consider social, economic and health equity impacts of AI-related research

**Challenge: emerging fields such as large language models create new and serious challenges in ensuring equity in AI-enabled medical devices**

Foundation models (AI models trained on vast amounts of data) such as large language models (LLMs) – as exemplified by ChatGPT – are magnifying uncertainty around equity impacts of digital technologies.

These technologies are already challenging existing ways of thinking and working, such as discussion about using ChatGPT to generate discharge summaries when patients leave hospital.\(^{157}\) ChatGPT is one example of Generative AI, which can create a wide variety of data such as images, videos, audio and text.\(^{158}\)

An area of particular risk is that these applications are trained on data from opaque sources, so it is difficult, if not impossible, to come to a clear view of the representativeness and appropriateness of the training data.

Outputs from LLMs can include ‘hallucinations’ – errors mixed in with facts. Examples have included generating the wrong date for when Leonardo da Vinci painted the Mona Lisa and claiming that George Washington, first president of the US, also invented the cotton gin.\(^{159}\)
7. Preventing bias in AI-enabled medical devices

It is impossible to predict the myriad of ways that LLMs and other foundation models will influence medical device innovation. No doubt there will be many beneficial developments, but it is nonetheless vital that we start thinking and planning now about how to understand and address the risks.

*This review recommends that:*

**Recommendation 15:**

Regulators should be properly resourced by the government to prepare and plan for the disruption that foundation models and generative AI will bring to medical devices, and the potential impact on equity. A government-appointed expert panel should be convened, made up of clinical, technology and healthcare leaders, PPI representatives, industry, third sector, scientists and researchers who collectively understand the technical details of emerging AI and the context of medical devices, with the aim of assessing and monitoring the potential impact on AI quality and equity of large language and foundation models.
8. Future proofing: polygenic risk scores

Looking to the future, there is a set of new medical devices in genomics employing polygenic risk scores (PRS) under development that are of relevance to this review.

Although it will be some years before the NHS uses PRS routinely, there are important questions about equity and ethics that need to be addressed now, before they are introduced.

Our recommendations prioritise actions to tackle the societal challenges, incorporating an essential public health and patient perspective.

What are PRS and how are they used?

Common genetic variants are defined as those that occur at a frequency of more than 1% in the population. These variants, in the form of single nucleotide polymorphisms (SNPs or ‘snips’) can be associated with disease risk.

Each variant only has a small effect – if any – on the risk of a particular disease, so knowing that someone has a single variant does not provide any useful information when trying to predict the risk of developing conditions such as heart disease or Alzheimer’s. (This contrasts with rare genetic diseases such as cystic fibrosis and sickle cell disease, which are directly caused by a specific mutation.)

However, examining their collective impact has been identified as a potential mechanism for predicting disease risk. Aggregating information across multiple disease-associated SNPs (often millions) into a single combined score – a PRS – can be used to assess an individual’s genetic predisposition to a disease or trait, by providing a single measurement of the cumulative effect of many (individually low-impact) genetic changes for a specific disease.160

Even though PRS are not a strong measure of genetic risk, they could be used as additional information, along with other details about an individual, to refine risk assessment and guide clinical decisions.

Uses of PRS could include improving risk prediction, informing and targeting disease screening, aiding diagnosis and informing treatment decisions. For an individual, they could influence life and lifestyle planning.161 Genome UK hails them as “offering a step change” to a new generation of risk prediction tools.162
For many common chronic diseases, PRS will not be used in isolation but added to risk scores already used in clinical practice to produce an integrated risk score or tool. For example, in diabetes a PRS could be added to the Leicester Diabetes Risk Score, and in ischaemic heart disease to the QRisk scores. These risk scores include physical measurements (for example, blood pressure), other biomarkers (for example, cholesterol) as well as demographics (e.g. age, sex, ethnicity) and measures of deprivation. That is why it is important people from disadvantaged backgrounds (who have generally been under-represented in research) are included in the development of integrated risk scores.

**Box 10: Key properties of polygenic risk scores**

Key properties of polygenic risk scores:
- PRS are a measure of genetic predisposition to a disease or trait
- PRS provide an estimate of the genetic contribution to risk of a disease
- PRS only capture a small proportion of genetic risk and an even smaller proportion of overall risk of the disease
- overall risk of disease will have non-genetic influences, such as socio-economic and environmental factors
- information from PRS analysis is neither deterministic nor highly predictive, especially by itself

**What are the equity concerns?**

There are two areas of concern:
- the ethnic bias historically seen in most large genetic datasets employed to develop PRS
- societal challenges, including vulnerability of PRS information to misinterpretation and misuse

**Ethnic and other unfair biases in genetic datasets**

There is a well-recognised bias in the genetic datasets used in genome research. They are heavily skewed towards people of European ancestry. In the UK Biobank, for example, which is the largest and most widely used dataset of its kind in the world, 94.6% of the 500,000 participants are classed as White (assumed to be European ancestry), 1.6% are classed as Black or Black British and 1.6% British South Asian.

People from more disadvantaged socio-economic groups are also significantly under-represented. In the most recent review of ethnic and other biases in genome-wide association studies (GWAS) for the most common non-communicable diseases, the
vast majority (91%) of complex trait GWAS had been performed in European ancestry populations.\textsuperscript{164} This means, for example, that people of African or Asian descent are seriously underrepresented, so PRS will typically be less accurate in their predictions when applied to people with non-European ancestry.

Genetic diversity matters because different ancestral populations have acquired different genetic variants during human evolution, so the genetic variants that play a role in their health and disease will differ.

The lack of diverse genomic datasets that represent different genetic ancestral populations is now widely acknowledged as one of the causes of the observed bias in PRS.\textsuperscript{165} There is an obvious and serious risk that polygenic scores could exacerbate existing ethnic inequities in health, such as by wrongly excluding or including people from certain ethnic groups for particular tests or treatments. This is a major ethical and scientific challenge for implementing PRS in the NHS.\textsuperscript{166}

**Investments already made in improving diversity**

There has been substantial investment in the UK to maintain the country's position as a global leader in the field of genomics, including as a founder of PRS research. Tackling the bias in genomic datasets – specifically lack of datasets representative of different genetic ancestral populations – has therefore been made a national priority. The government’s 10-year genomics strategy promises:

- “we will develop robust systems of outreach and communication to diversify our genomics datasets. This will address the ethnic bias historically seen in most large genetic datasets and help ensure equity of access to genomic healthcare”\textsuperscript{167}
- “over the next ten years, we will: achieve greater diversity within our reference genomes, and future Genome Wide Association Studies (GWAS) will reflect the UK’s diverse populations.”\textsuperscript{168}

National investments to tackle the genetic ancestry diversity issue are well-developed and include:\textsuperscript{169}

- UKRI investing £79 million (of the total of around £250 million from UKRI, medical charities and the life sciences industry) to help establish a new genomics cohort dataset – Our Future Health – to increase ethnic diversity in future GWAS, as well as improving representation of more disadvantaged socio-economic groups (see Box 11 for recruitment strategies employed by Our Future Health). With an ambition to recruit up to five million participants, including one million from ethnic minority and more disadvantaged socio-economic groups, Our Future Health plans to genotype the world's largest population cohort to support the early detection of disease
- UK Biobank developing a secure and scalable genome variant imputation service to enrich data collected by Our Future Health
8. Future proofing: polygenic risk scores

- Genomics England three-year diverse data programme, which includes tailored sequencing of 15,000 to 25,000 participants from ancestry groups that are currently under-represented in genomic research.
- Genes and Health, researching up to 100,000 participants from British-Bangladeshi and British-Pakistani ethnic minority groups, who are poorly represented in other large genetic research studies to date. The aim is to build a long-term population health resource combining genetic data and lifetime NHS health record data.

A host of international initiatives is tackling the lack of genetic ancestry diversity in studies. These include the All of Us Research Program funded by National Institutes of Health (NIH) to invite one million people across the US to help build one of the most diverse health databases in history, the US NIH-funded PRIMED Consortium and the EU Horizon 2020 INTERVENE Core consortium.

Box 11: Our Future Health – improving diversity of datasets

Our Future Health aims to be the world’s largest population cohort by recruiting up to five million adult volunteers to provide genetic and other data to help researchers find new ways to prevent, detect and treat illnesses.

Its aim is to build a resource that has improved genetic diversity with respect to ethnicity and genetic ancestry, together with improved representation of socio-economic status, so that the cohort is representative of the UK population. The recruitment strategy includes:

- prioritising trial sites in disadvantaged areas and locations with higher concentrations of ethnic minority populations
- offering reimbursement and patient-centred approaches including easily accessible clinic venues to overcome logistical, financial and cultural barriers which limit participation of ethnic minority groups and disadvantaged socio-economic groups in the study
- providing recruitment documents in multiple languages and employing multilingual research staff and interpreters
- working with patient advocacy groups and communities to address participant needs, and remaining engaged with communities
- providing field workers with cultural competency and proficiency training to facilitate building of trusting relationships with communities
- soliciting expertise from diverse stakeholders to advise on data analysis, especially from those groups whose data are typically under-represented in genomic research.
We commend these concerted attempts to address the genetic ancestry bias in source genetic datasets, which should, in the long-term, improve the genetic diversity of the research platforms from which PRS are drawn. The recruitment strategies employed by Our Future Health provide examples of good practice. We conclude that further recommendations on this technical side are not required, but rather it is the wider societal challenges that are in danger of being neglected and will need attention in the coming years.

**Recommended action to address the societal challenges**

The equity issues surrounding PRS go beyond the technological challenge of improving diversity of the genetic datasets. If we want to harness the potential benefits of PRS and avoid the harm then we must pay more attention to the societal challenges and the real-world context in which PRS will be implemented.

**Greater attention to interactions with social determinants of health**

The first societal challenge is the possible disruption that PRS may bring to long-standing efforts to tackle modifiable risk factors for disease. PRS are set to be introduced, for example, as part of integrated risk scores for common, multi-causal diseases, for which there are already well-established risk factors related to the social determinants of health that can be modified. For many common diseases, non-genetic factors such as smoking, poor nutrition, socio-economic deprivation and inadequate living and working conditions, matter more than a person’s genetic makeup\(^{172}\) and, moreover, are socially patterned, contributing to inequities in health.\(^{173}\)

Yet there is a danger that the spotlight and resources will be drawn to the PRS component of integrated risk scores, putting undue emphasis on the genetic component of the risk. There is also a gap in our understanding of the interactions between the genetic risk factors for common diseases as identified by PRS and the social determinants of health and whether, for example, the interaction leads to differential vulnerability.\(^{174}\) Such interaction studies are needed for interpretation and application of information from PRS analyses.

*This review recommends that:*

**Recommendation 16:**

The focus of PRS studies should be widened beyond genetic diversity to include the contribution of the social determinants of health – including lifestyle, living and working conditions and environmental factors such as air pollution – to overall disease risk, and how these affect the predictive potential of PRS among different ethnicities and socio-economic groups.
Developments with this wider research focus should aid the refinement of overall risk assessments so they better reflect the role that PRS play alongside non-genetic risk factors.

**Vulnerability of PRS information to misinterpretation**

The second societal challenge is that PRS have the potential to be misunderstood by members of the public and cause distress. The potential for misunderstanding and miscommunication of the meaning of PRS across the population is considerable, raising concerns about adverse consequences of integrating PRS into, for example, population-wide screening programmes.175, 176, 177

It is important to recognise that PRS are not diagnostic and cannot accurately predict whether an individual will develop a disease or condition. A high-risk score does not mean a person will definitely develop a condition, and a low score does not mean they will not. Instead, PRS provide an estimate of risk for a group of people like the individual based on their genetic makeup.

Other factors, however, beyond genetics must also be taken into account when considering an individual’s overall risk of common diseases that we know have multiple causes. Without this understanding, mistaken deterministic beliefs could lead to health-damaging decisions.

Box 12 illustrates some mistaken deterministic beliefs when members of the public explain how they interpret PRS reports.

**Box 12: examples of mistaken deterministic beliefs when presented with mock polygenic risk score reports**

These quotes are from patients in a US qualitative study explaining how they interpret mock PRS reports, one report indicating that the fictional patient was ‘high risk’ for a disease and one ‘not identified as at high risk’:

Many mistook percentile for percent chance: “He’s almost at a full whole risk. Ninety-nine percentile is almost at one hundred, so it’s like you’re one percent away from being completely at all risk of getting it. Doesn’t matter what age it is, you’re going to get it, that’s the thing.”

Another common misinterpretation was to confuse ‘not high risk’ with ‘low risk’. The ‘high risk’ reports were often linked to a sense of genetic determinism: that they are going to develop the condition:

“Just made me feel like I have the disease, whatever it is.”
"I mean, it gets to the point, but, me being the person that I am and not knowing too many big words, a lot of this would kind of scare me ... just seeing the 'high risk', I probably would think that ‘Oh, my God, I’m going to get cancer.’"

"It tells you for real, tells you to start getting ready. But I would die, it’s very severe. Very alarming, very severe, it would make me worried.”

Source: Public perceptions and quotations from Anna Lewis and others, 2022

The problem is compounded by frequent confusion about absolute risk versus relative risk when interpreting risk scores. Table 2 shows different ways of presenting the lifetime risk for a person in the top 5% of polygenic risk scores for that specific disease.

They could be given PRS results in relative risk terms. For colorectal cancer, for example, the person could be given the news that they are in the ‘high risk’ category, because their score is within the top 5% of polygenic scores for people of their age and sex. They could be told that they had 1.5 times higher risk of this cancer than the background population risk, or that they have a 50% higher risk of colorectal cancer than normal. In absolute terms, they could be told that they have a 6.9% lifetime risk of developing colorectal cancer against an underlying population risk of 4.6%.

Without public and health professionals’ understanding of these limitations, PRS are vulnerable to misinterpretation. Improper risk communication may result in physical or financial harm to the members of the public receiving the communication, because of unnecessary lifestyle or clinical interventions, as well as unwarranted effects on mental health such as anxiety or depression.

Table 2: Different ways of presenting the lifetime risk for a person in the top 5% of polygenic risk scores for that specific disease

<table>
<thead>
<tr>
<th>Disease</th>
<th>‘High risk’ or ‘not high risk’</th>
<th>Individual lifetime risk</th>
<th>Background population risk</th>
<th>Relative risk compared to background risk</th>
<th>% higher or lower risk compared to normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorectal cancer</td>
<td>‘high risk’</td>
<td>6.9%</td>
<td>4.6%</td>
<td>1.5 times higher than population risk</td>
<td>50% higher risk than normal</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>‘high risk’</td>
<td>2.1%</td>
<td>1.6%</td>
<td>1.3 times higher than population risk</td>
<td>30% higher risk than normal</td>
</tr>
</tbody>
</table>

Source: constructed from Sud and others, 2023

There are gaps in our knowledge of public understanding of high and low polygenic risk, whether there is a particular problem of beliefs about genetic determinism associated with PRS which would influence attempts at behaviour change, the extent of miscommunication between public and health professionals, and how best to improve communication, support and counselling services for individuals receiving
PRS reports. These gaps could be filled by new research. The findings of any proposed research programme could feed into the ongoing evaluation of this technology for widespread use.

*This review recommends that:*

**Recommendation 17:**

National research funders should commission a broad programme of research and consultation with the public, patients and health professionals to fill the gaps in knowledge and understanding concerning PRS. The programme should cover both the public’s understanding of the nature of genetic risk and the meaning of the PRS they are presented with, together with explorations of how health professionals interpret these risks and can best communicate and support people in understanding the results of their PRS.

The research programme should cover impacts on diverse population sub-groups, and be informed by extensive engagement with the public and patients to gain their perspectives.

Results from this research programme, together with actions on recommendation 16, should feed into the development of clinical applications for PRS medical devices, covered in recommendation 18.

**Guidance for clinicians on PRS application**

The third challenge for society, and the NHS in particular, is a more immediate one. Although PRS are not yet introduced in the NHS, they are already being used in a haphazard way with little or no regulation in other countries, and they are trickling into the UK through commercial, direct-to-consumer routes without any regulation or support for the people who receive this sort of information.

For example, there is a thriving internet business in ancestry testing, and for a small extra fee companies offer ‘medical testing’ through secondary analysis. This unregulated testing increases the risk of misleading or misinterpreted results creating anxiety.¹⁸³

Even if an individual has access to an effective genetic test they may not have access to the necessary support for interpreting and acting on the results, such as genetic counselling, possibly leading them to go to their GP to try to understand it after a lot of avoidable worry.

Embryo selection based on pre-implantation PRS testing is on the horizon, raising many complex ethical issues.¹⁸⁴ Although the practice is currently prohibited in the UK, it is already being offered by overseas companies, and the availability of the technology abroad will test the limits of UK regulation.
Health professionals, therefore, are already having to wrestle with challenges and dilemmas concerning PRS in their day-to-day clinical practice. So far there are no clinical guidelines available for the use of this technology. Guidance is needed to help professionals navigate through and understand the challenges and limitations of the technology, such as how best to counsel a patient who turns up with a PRS test result. Box 13 gives an example of some emerging guidance from the American College of Medical Genetics and Genomics.

**Box 13: clinical application of polygenic risk scores**

This is a summary of American College of Medical Genetics and Genomics ‘points to consider statement’, including patient and public engagement with testing, the implications of using testing in different populations and clinical management and follow-up.

PRS test results do not provide a diagnosis, they provide a statistical prediction of increased clinical risk.

A low PRS does not rule out significant risk for the disease or condition in question.

If the risk prediction of a PRS is derived from a population that is different from the patient being tested the results may have a poor predictive value for the patient.

Isolated PRS testing is not the appropriate test when a single genetic cause is known or suspected.

Before testing, a patient should discuss what it may show and how the results will be used to guide medical management.

PRS-based medical management should be evidence-based. However, there is currently limited evidence to support the use of PRS to guide medical management.

PRS testing of preimplantation embryos is not yet appropriate and should not be offered.

Source: Based on American College of Medical Genetics and Genomics, 2023.

*This review recommends that:*

**Recommendation 18:**

UK professional bodies such as the royal colleges and the health education bodies across the UK should develop guidance for healthcare professionals on the equity and ethical challenges and limitations of applying PRS testing in patient care and population health programmes.
The guidance should:

- include the interpretation of risk scores, communicating risk to patients and the public and counselling and support
- be informed by extensive public and patient engagement
9. Horizon scanning and next steps

During our review we have noted several issues regarding equity in medical devices looming on the horizon. Some are topics that were out of scope for this review, but nevertheless raise important equity issues for the future. We highlight here the continuing growth of wearables that are crossing over from personal well-being improvement devices to medical devices, the continuing challenge of inequities in access to medical devices – made all the more critical with the growth of the digital health divide – and a pressing need to improve equity in medical devices used routinely in pregnancy and the neonatal period.

Wearables

The first is the advent of wearables – electronic devices such as smartwatches and fitness trackers designed to be worn on the user’s body. Many devices collect health-related data such as heart rate, blood pressure, sleep patterns and physical activity using biosensors on the wearer’s skin.

Currently they are largely marketed to consumers as ‘wellbeing devices’ and so are not subject to medical device regulations. As such they were outside the scope of our current review. During the course of our review, however, we discovered that there are many clinical applications under development, including for cardiovascular management and mental health monitoring, which would eventually bring them into the category of ‘medical device’.

What are the equity issues? They have the potential to suffer from the same kind of biases inherent in the medical devices in our review. For example, if they use optical techniques through the skin to track physiological change, they may not be as accurate, or may not work at all, in people with darker skin tones. The ability of smartwatches to track heart rates in people with dark skin is already being questioned. Testing of the devices on mainly White participants is a familiar underlying problem.

The large datasets on which the algorithms that are driving these devices draw are likely to be unrepresentative of ethnic minority and more disadvantaged socio-economic groups because of the well-known bias in recruitment to such studies. This is compounded in digital studies by a common requirement for participants to have their own expensive piece of equipment, such as a smartwatch. One such study of the accuracy of an arrhythmia detection algorithm requiring ownership of an Apple
product was found to be biased towards a young, wealthy and technology-savvy population.\textsuperscript{189} This may render the algorithms only applicable to more affluent groups reflecting the study composition.

Then there are potential equity issues with the internal algorithms and computational models being developed for applications in psychiatry, whether for mental illness detection, prediction or individualisation of treatment.\textsuperscript{190} In many instances digital psychiatry is moving to online interactive platforms driven by AI algorithms that attempt to interpret the responses and language being used by ‘patients’ to describe their symptoms. But what is emerging from the literature is that current natural language processing algorithms being used on these platforms can be biased against certain ethnic groups because of the different ways people from different cultures and ethnicities express themselves.\textsuperscript{191}

It is clear that the equity implications of wearables used as medical devices will need to be assessed as a next step in preparation for their increasing adoption in clinical practice.

**Inequities in access to medical devices**

Second is the issue of inequitable access to medical devices or to the services they support. Again, this issue was judged out of scope of our review, though equitable access is noted as an important component of equity in the NHS system as a whole in section 3.

Essentially, we reviewed evidence related to medical devices causing biased selection of patients or exhibiting biased performance against one or more groups in the population. The separate equity issue of whether all population groups can gain access to effective medical devices on the basis of need was outside our remit and, indeed, draws on completely different evidence. Nevertheless, many access issues were brought to our attention during the review which we have been reflecting on.

What are the equity issues? With the advent of digital health technologies and recent genomic innovations, new manifestations of the inverse care law are emerging all the time. This ‘law’ (‘the availability of medical care tends to vary inversely with the need of the population served’\textsuperscript{192}) can be seen in the tendency for digital health innovations to be available and taken up more readily in more affluent groups and areas with better health profiles in the first place.

The concept of ‘digital poverty’ or ‘digital exclusion’ has been invoked to capture the experience of groups in society who do not have full access to the online world when they need it and so are excluded from the benefits of advances in digital services that are on offer. This exclusion could be because of cost, language barriers or technological proficiency.
In 2022, for example, a US study found that wearables and other digital devices were not used as widely in minority and low-income groups, with cost and education affecting use. Online services offered in primary care and telemedicine may benefit the staff but exclude the elderly, those with low educational attainment or poorer patients with the greatest need.

This concern about inequities in access to medical devices is also growing in relation to genomics. Once an effective but expensive pharmacogenomic treatment becomes available, for instance, questions arise about who gets it. But with the under-representation of certain ethnic groups in pharmacogenetic research, there will be far more uncertainty around the cost effectiveness of such tailored therapy in ethnic minority groups, casting doubt on the equitable allocation of scarce resources.

The issue of inequities in access to medical devices in the NHS has become even more pressing with the new technologies on the horizon. Addressing this is an essential task for the government and the NHS leadership.

**Equity in medical devices during pregnancy and the neonatal period**

Third is the special circumstances surrounding pregnancy and the neonatal period, when all women and their babies under the care of the NHS encounter a variety of medical devices in routine screening tests, some of which will have the potential for ethnic or socio-economic bias. This is a critical situation because of the marked ethnic and socio-economic inequities in pregnancy outcomes, which the NHS should be striving to reduce rather than exacerbate.

During our review, examples from the pregnancy and neonatal period came up in all three types of medical device we studied. But studying potential bias in individual medical devices could not give a complete picture of the cumulative effect that exposure to a variety of devices might have if encountered over a nine-month period.

An alternative approach would be to start from the perspective of patients rather than the devices. This approach would be to follow women’s experiences with the various tests and devices throughout pregnancy, and whether subsequent pregnancy outcomes differed by ethnic or socio-economic group.

As a first step towards this approach, we commissioned a rapid review of the evidence taking such a perspective, which found evidence of the potential for ethnic bias in three of the routine tests classed as medical devices in pregnancy and three for newborn babies. There was also evidence of adjustments that reduced or eliminated the bias in the devices in some instances.

It was clear, however, that there were substantial scientific debates in this field about the best course of action to tackle the identified ethnic bias in the devices and, indeed, whether the ethnic disadvantage observed in specific health conditions in pregnancy was attributable to the effects of socio-economic disadvantage, rather than to distinct ethnic differences. The task of building a consensus as a basis for recommendations
to improve equity in medical devices used along the pregnancy pathways is therefore a substantial undertaking in its own right, and one that needs to be carried forward with some urgency.

Our final call for action as a next step, therefore, is that a review should be carried out of equity in the medical devices encountered during pregnancy and the neonatal period, as part of the wider investigations of health outcomes for ethnic minority and poorer women and their babies.
Appendix A: terms of reference for the Independent Panel

Purpose

The purpose of the review is to establish the extent and impact of potential ethnic and other unfair biases in the design and use of medical devices and to make recommendations for more equitable solutions.

Context

A core responsibility of the NHS is to maintain the highest standards of safety and effectiveness of medical devices currently available for all patients within its care. Evidence is emerging about the potential for ethnic bias in the design and use of some medical devices commonly used in the NHS, and that the treatment of patients from some ethnic groups may be less effective as a result.

An illustrative example relates to devices employing infrared light or imaging which may perform differently depending on the skin pigmentation of the patient. Some studies of pulse oximeters, for example, have found that inaccurate readings are more common in Black patients than in White patients and that some devices consistently overestimate blood oxygen levels in darker-skinned patients. Potentially, this means that dangerously low oxygen levels could be missed in these patients, with adverse health consequences. Some devices were originally developed in populations that were predominantly white and the calibration of the devices was carried out against these lighter skin tones, potentially resulting in unintended ethnic bias.

Another substantial line of enquiry for the review concerns artificial intelligence (AI) tools, used in healthcare, and whether their algorithms have in-built biases. It has been demonstrated, for example, that advanced clinical prediction models underperform on women, ethnic minorities and poorer groups, partly because these population groups are under-represented in the data sources for the models. This issue is of growing importance because such predictive algorithms are increasingly used to support crucial decision-making tasks in healthcare - from prevention to diagnostics to therapeutics. The risk of biases that lead to differentially harmful decisions for patients in certain population groups is increasing.

It is important that this review establishes the extent and impact of such potential ethnic and other unfair biases in the design and use of medical devices used in the NHS and what can be done to remedy it.
Appendix A: terms of reference for the Independent Panel

Scope

The review will focus on those products classified as medical devices under current GB and EU regulations and in use across the UK. The definition of ‘medical devices’ includes not only physical instruments and machines, but also artificial intelligence tools and software increasingly used to assist crucial diagnostic or therapeutic decision making, as well as AI derived predictive analytics including those based on genomics data. The Review will also be future-focused and consider the enhanced risk of bias in the emerging range of such tools.

It will review the current regulatory framework for approving medical devices and consider any proposed changes by the MHRA following its recent consultation on this framework and form a view on whether additional actions should be taken to mitigate risks. Recommendations on relevant training for health professionals will also be made.

The review chair will issue the panel’s report to the Secretary of State for Health and Social Care setting out clear options for consideration. The government will publish the report of the review and the government’s response.

Questions to be addressed

The review panel will be asked to make an assessment in relation to the following questions:

- How far reaching is the problem?
- Where medical devices do not function equally well for all ethnic groups, is the scale of this difference of clinical significance, and could it cause adverse health outcomes for some ethnic groups?
- What could be done to mitigate such adverse outcomes?
- How effective are any such mitigations?
- What further action should be taken to address these issues?

In addition, the review will make recommendations in relation to preventing potential ethnic and other inequalities related to the design and use of medical devices, including unintended or implicit bias. These recommendations will cover the following:

- How to address potential ethnic and other unfair biases, including through a whole-system approach – from design to use?
- What role could and should regulation play in removing identified bias?
- What systems needs to be in place to ensure emerging technologies, including software, artificial intelligence and genomics-based tools as medical devices are developed without inbuilt ethnic and other unfair biases?
- How can the UK drive forward international standards to improve healthcare and promote equity in medical devices?
Appendix B: panel members’ biographies

Professor Dame Margaret Whitehead (Chair)

Professor Dame Margaret Whitehead holds the WH Duncan Chair of Public Health at the University of Liverpool, where she was also founding Head of the World Health Organization (WHO) Collaborating Centre for Policy Research on the Determinants of Health Equity from 2005 to 2020.

Her passionate interest over the past 30 years has been inequalities in health and in healthcare – most especially what can be done to tackle these inequalities. Her work with WHO has helped provide guidance for countries across Europe on making population health policies and strategies more equitable.

As well as contributing to various UK and international efforts to address social inequalities in health, she chaired the Independent Inquiry into Health Equity for the North of England (the Due North Report), which set out recommendations for northern agencies to work together across sectors, as well as for central government to play its full part. In 2016 she was awarded a damehood for services to public health with special reference to her research on inequalities in health.
Professor Raghib Ali

Professor Raghib Ali is the Chief Executive Officer, Chief Medical Officer and Chief Investigator of Our Future Health; a Clinical Epidemiologist at the University of Cambridge; a Consultant in Acute Medicine at the Oxford University Hospitals NHS Trust; and Director of the Public Health Research Center and Research Professor at New York University Abu Dhabi.

He is also an Associate Fellow at Green-Templeton College, University of Oxford and an Honorary Consultant in the Office for Health Improvement and Disparities.

He graduated from Cambridge University in 2000 with the award of the John Addenbrookes Prize for Medicine and has subsequently received postgraduate degrees in Epidemiology and Public Health from the Universities of London, Cambridge and Oxford. He is a Fellow of the Royal College of Physicians.

He has been involved in population health and inequalities research since 2004 nationally and globally, working firstly on UK Biobank, then leading studies of cancer incidence by ethnic group in England and India from 2005 to 2013 and then established the UAE Healthy Future Study in 2014, for which he is the principal investigator.

He voluntarily returned to frontline clinical duties during the pandemic and was also appointed as an Independent Expert Adviser on Covid-19 and ethnicity to the Race Disparity Unit, helping to implement policies to reduce the increased risk faced by ethnic minorities. He also played a leading advocacy role in building trust and improving the uptake of the Covid vaccine in ethnic minorities.

He was awarded an OBE in the Queen’s Birthday Platinum Jubilee Honours 2022 for services to the NHS and the COVID-19 response and elected as an Honorary Fellow of the Faculty of Public Health in April 2023, ‘the highest accolade the Faculty can bestow and is awarded to those who have given exceptional service to the science, literature or practice of public health’.
### Professor Enitan Carrol

Professor Enitan Carrol is Clinical Director of the National Institute for Health Research's Clinical Research Network in the North West Coast, and a Professor of Paediatric Infection at the University of Liverpool. She is also an Honorary Consultant in Paediatric Infectious Diseases, Alder Hey Children's Hospital in Liverpool.

Professor Carrol previously served on the SAGE ethnicity sub-group, and contributed to evidence reports on the impact of COVID-19 on ethnic minority groups. Her research interests include bacterial infections in children and early recognition of sepsis, and clinical trials evaluating biomarkers to guide antimicrobial stewardship decisions. She has over 25 years’ experience of clinical research in hospitalised children with infections.

She has a special interest in the development and testing of risk prediction tools using routinely collected electronic patient data. She sits on the MRC Developmental Pathway Funding Scheme and NIHR Invention for Innovation (i4i) Programme funding panels.

### Professor Chris Holmes

Professor Chris Holmes is Programme Director for Health and Medical Sciences at The Alan Turing Institute, and Professor of Biostatistics at the University of Oxford.

At Oxford, Holmes holds a joint appointment between the Department of Statistics and the Nuffield Department of Clinical Medicine through the Wellcome Centre for Human Genetics and the Li Ka Shing Centre for Health Innovation and Discovery.
Before joining Oxford, Holmes was a faculty member at Imperial College London, and before that he worked in industry conducting research in scientific computing. He holds a Programme Leader’s award in Statistical Genomics from the Medical Research Council UK. He serves on the international advisory board for UK Biobank, the technical advisory board for Our Future Health, and the NHS AI Award Evaluation Advisory Group. He co-leads the European ELLIS Society’s programme on Robust Machine Learning.

Professor Holmes has a broad research interest in the theory, methods and applications of statistics, causal inference, and machine learning for applications in health. He is particularly interested in Bayesian statistics and robust statistical machine learning in genomics and genetic epidemiology.

**Professor Frank Kee**

Professor Kee is the Director of the Centre for Public Health in the School of Medicine, Dentistry and Biomedical Sciences at Queen’s University, Belfast, and previously directed one of the UKCRC Centres of Excellence for Public Health Research (2008-2018).

He serves on a number of UKRI scientific advisory and funding panels including the MRC Better Methods for Better Research Panel and the Longitudinal Studies Advisory Group, having previously served on the MRC Population and Systems Medicine panel and the Public Health Intervention Development Panel.

He previously chaired the NIHR Public Health Funding Board (until 2019) and sits on the Advisory Board for the NIHR School of Public Health and the Methods Advisory Group of the Department of Work and Pensions.

Professor Kee’s interests span a wide range of subjects in epidemiology, public health, health services research and complexity science and in finding better ways to evaluate the impact of our academic endeavours, both methodologically and in terms of knowledge mobilisation that can impact policy and practice.

Professor Kee maintains active collaborations with international cardiovascular epidemiology consortia, including the development of risk prediction tools and with a range of methodologists developing novel methods for evaluation of complex systems and complex interventions in public health.
Appendix C: engagement activities and acknowledgements

The Independent Review carried out an array of engagement activities with a wide range of stakeholders, as detailed in section 1. This section lists and thanks these contributors.

Acknowledgements

The chair and panel would like to thank the many stakeholders who contributed to the review’s work. The evidence, insights, and suggestions that they shared played a crucial role in shaping the review and its recommendations.

Special thanks go to several individuals and organisations for their significant and ongoing support throughout the review:

• to the outstanding secretariat – Dr Aleksandra Herbec, Maya Grimes and Jessica Scott – who have been enthusiastic and dedicated in their support for the work of the review throughout. Their unswerving support has made all the difference
• to Dr Lisa Cromey, who joined us on secondment from the Northern Ireland Postgraduate Specialist Training Scheme in Public Health, and played a critical role in our research and the development of our recommendations
• to the Alan Turing Institute for its generous support throughout, including hosting our panel meetings over 15 months, and our in-person roundtables
• to the authors and contributors of our commissioned reports and patient-focused vignettes, prepared on behalf of the Review. Particular thanks go to Professor Daniel Martin for his ongoing advice throughout, over and above his commissioned work

We appreciate the time and expertise of everyone involved in our various engagement activities, and list them below.

Patient involvement in animation

The review would like to thank the Cambridge University Hospitals PPI Panel for contributing to the development of an animation to accompany the final report, and providing invaluable insights from a patient and public perspective.
In particular, we would like to thank the following panel members:

- Jeremy Dearling
- Ruth Katz
- Amy Lafont
- we would also like to thank Amanda Stranks for coordinating and facilitating this patient engagement

**Individual or group meetings**

- Accelerated Access Collaborative, NHS England – Daniel Bamford, Sarah Tyers
- Ada Lovelace Institute – Carly Kind, George Lloyd-King, Dr Mavis Machirori, Imogen Parker, Dan Steer
- AHSN Network – Stuart Monk
- The Alan Turing Institute – Professor David Leslie
- Association of British HealthTech Industries – Eleanor Charsley
- British Association of Dermatologists – Emma Lennard, Dr Rubeta Matin, Tania von Hospenthal
- British Standards Institution – Graeme Tunbridge, Rob Turpin
- College of Computing, Georgia Tech – Dr Munmun De Choudhury
- Department of Anesthesia and Perioperative Care, University of California, San Francisco – Dr Michael Lipnick
- Department of Health and Social Care – Marian Holliday, Charlette Holt-Taylor, David Lawson
- Dorset Innovation Hub, University Hospital Dorset – Sarah Chessell
- Faculty of Engineering Science, University College London – Dr Luís Miguel Lacerda, Dr Evalngelos Mazomenos
- Genomics England – Dr Maxine Mackintosh
- Guy’s and St Thomas’ NHS Foundation Trust – Dr Haris Shuaib
- The Health Foundation – Dr Jennifer Dixon, Tom Hardie, Josh Keith, Catriona Rutherford, Charles Tallack
- Health Technology Wales – Sophie Hughes
- Healthcare Governance, Welsh Government – Ian Thomas
- Information Commissioner’s Office – Sophia Ignatidou, Alister Pearson
- Innovation for Healthcare Inequalities Programme, NHS England – Victoria Spellacy
- Institute of Cancer Research, London – Dr Amit Sud
- Institute of Inflammation and Ageing, University of Birmingham – Professor Alastair Denniston, Dr Xiaoxuan Liu
- Institute of Population Health, University of Liverpool – Professor David Taylor-Robinson
Appendix C: engagement activities and acknowledgements

- Medical Devices and Legislation Unit, Scottish Government – Kerry Chalmers
- The MHRA – Dr Katherine Donegan, Mark Grumbridge, Louise Loughlin, Jenn Matthissen, Dr Louise Mulroy, Johan Ordish, Dr Russell Pearson, Phil Tregunno, Dr Paul Campbell, Suzanne Fuller, Dr Janine Jolly, Nathan Moore, Dr Glenn Wells, Dr Penny Wilson
- National Institute for Health and Care Excellence – Rebecca Albrow, Dr Sarah Byron, Dr Felix Greaves
- NHS AI Lab, NHS England – George Onisiforou, Rory Pringle
- NHS Confederation – Ruth Lowe, Hashum Mahmood
- NHS England – Professor Dame Sue Hill, Sarah Jennings, Professor Bola Owolabi
- NHS Race and Health Observatory – Owen Chinembiri, Janet Evans, Marie Gabriel CBE, Dr Habib Naqvi
- NHS Resolution – Laura Hunter, John Mead, Helen Vernon
- NHSX – Vicki Beresford, Leanne Summers
- Nuffield Department of Primary Care, University of Oxford – Professor Trish Greenhalgh
- Office for Artificial Intelligence – Rob Howieson, Laura Lean, Thomas Slater
- Office of National Statistics – Emma Rourke, Dr Nick Taylor
- Patient Safety Commissioner for England – Dr Henrietta Hughes
- Patients Association – Rachel Power, Shivani Shah
- Peninsula Medical School, University of Plymouth – Professor Daniel Martin
- Perinatal Institute, Birmingham – Emily Butler, Professor Jason Gardosi
- PHG Foundation – Dr Laura Blackburn, Dr Mark Kroese, Dr Colin Mitchell, Dr Sowmiya Moorthie
- Race Disparity Unit, Cabinet Office – Vasileios Antonopoulos, Clarissa Natel, Dominic Smales, Kate Cranston-Turner
- Regulatory Horizons Council, Department for Science, Innovation and Technology – Katie Francis, Tanuj Jain
- Scottish Health Technologies Group – Edward Clifton, Dr Safia Qureshi
- Tommy’s National Centre for Maternity Improvement – Professor Basky Thilaganathan
- US Food and Drug Administration – Erin Cutts, Dr Malvina Eydelman, Aja Hardy, Dr Kumudhini Hendrix, Anahit Kyshtoyan, Bray Patrick-Lake, Dr James Lee, Neil Mafnas, Dr Allison O’Neill, Anindita Saha, Dr Michelle Tarver, Melissa Torres
- Wellcome Centre for Human Genetics, Oxford University – Professor Anneke Lucassen
- Yorkshire & Humber Clinical Effectiveness and Audit Regional Network – Victoria Patel
Commissioned reports

Rapid review: potential unfair biases in optical medical devices
• Barking Havering and Redbridge University NHS Trust – Dr Mandeep Phull
• Faculty of Medicine, University of Southampton – Professor Eugene Healy
• Great Ormond Street Institute of Child Health, University College London – Professor Mark Peters
• Library and Digital Support, University of Plymouth – Chris Johns
• Peninsula Medical School, University of Plymouth – Professor Daniel Martin

A rapid review of potential biases in medical devices encountered in pregnancy and the neonatal period
• Institute of Population Health, University of Liverpool – Dr Nicholas Adjei, Dr Oluwaseun Esan, Dr Ruairaidh Hill, Paris Lee, Dr Michelle Maden, Philip McHale, Dr Mikhailia McIntosh, Samira Saberian, Professor David Taylor-Robinson

Evidence around health equity in AI-enabled medical devices
• The Alan Turing Institute – Professor David Leslie

Polygenic scores: background paper
• PHG Foundation – Rebecca Bazeley, Phillippa Brice, Ofori Canacoo, Dr Mark Kroese, Dr Colin Mitchell, Dr Sowmiya Moorthie

Commissioned patient-focused scenarios

The impact of device inequity on individuals’ experience and outcome when presenting with an acute respiratory illness
• Institute of Inflammation and Ageing, University of Birmingham – Dr Joe Alderman, Professor Alastair Denniston

The impact of device inequity on individuals’ experience and outcome when presenting with a sight-threatening eye disease
• Cambridge University Hospital – Professor Rupert Bourne
• Institute of Inflammation and Ageing, University of Birmingham – Professor Alastair Denniston
A typical clinical pathway for a patient with an acute medical condition leading to low blood oxygen levels and

A possible clinical pathway for a patient from noticing a skin lesion to receiving definitive treatment for it

- Barking Havering and Redbridge University NHS Trust – Dr Mandeep Phull
- Faculty of Medicine, University of Southampton – Professor Eugene Healy
- Great Ormond Street Institute of Child Health, University College London – Professor Mark Peters
- Library and Digital Support, University of Plymouth – Chris Johns
- Peninsula Medical School, University of Plymouth – Professor Daniel Martin

Written submissions

- British Medical Association – Professor David Strain
- Cambridge University Hospitals PPI Panel – Vivienne Northrop, Amanda Stranks
- The Health Foundation – Tom Hardie, Charles Tallock, Malte Gerhold
- Institute of Population Health, University of Liverpool – Professor Sally Sheard
- Liverpool Women’s NHS Foundation Trust – Dr Umbar Agarwal
- MedConfidential – Sam Smith
- The MHRA – Louise Loughlin, Jenn Matthissen, Dr Louise Mulroy, Johan Ordish, Dr Russell Pearson, Suzanne Fuller
- NHS Race and Health Observatory – Dr Habib Naqvi
- Nuffield Department of Primary Care, University of Oxford – Professor Trish Greenhalgh
- Patient Safety Commissioner for England – Dr Henrietta Hughes
- Perinatal Institute, Birmingham – Professor Jason Gardosi
- STANDING Together initiative – Professor Alastair Denniston
- Tommy’s National Centre for Maternity Improvement, London – Professor Basky Thilaganathan
- Wellcome Centre for Human Genetics, Oxford University – Professor Anneke Lucassen

Call for evidence

We received 44 submissions to our call for evidence via the online portal, and a further 7 submissions via email. Responses came from a wide range of organisations and sectors, including device industry, healthcare providers, research, academia, standards and practice, and a variety of medical specialities. Further information can be found in Appendix D.
Roundtables

Optical devices

- Association of British HealthTech Industries – Luella Trickett
- Department of Anesthesia and Perioperative Care, University of California, San Francisco – Dr Michael Lipnick
- Department of Health and Social Care – Freya Rowland
- The MHRA – Jenn Matthissen, Dr Louise Mulroy
- National Institute for Health and Care Excellence – Dr Sarah Byron
- NHS England – Dr Dianne Addei
- NHS Race and Health Observatory – Sam Rodger
- Nottingham University Hospitals – Professor Daniel Clark
- Peninsula Medical School, University of Plymouth – Professor Daniel Martin
- Race Equality Foundation – Jabeer Butt
- Scottish Health Technologies Group – Dr Safia Qureshi
- U.S. Food and Drug Administration – Dr Malvina Eydelman

AI-enabled devices – regulators, academia and experts

- Ada Lovelace Institute – Andrew Strait
- British Standards Institution – Dr Aris Tzavaras
- Department of Health and Social Care – David Lawson
- The Health Foundation – Josh Keith
- Institute of Inflammation and Ageing, University of Birmingham – Professor Alastair Denniston, Dr Xiaoxuan Liu
- The King’s Fund – Pritesh Mistry
- The MHRA – Johan Ordish, Dr Russell Pearson
- NHS AI Lab, NHS England – George Onisiforou
- Office for National Statistics – Emma Rourke
- School of Computing, University of Leeds – Professor Alejandro Frangi
- Tommy’s National Centre for Maternity Improvement – Professor Basky Thilanganathan

AI-enabled devices – industry, academia and experts

- Alan Turing Institute – Professor David Leslie
- Association of British HealthTech Industries – Andrew Davies
- Emis Health – Alex Eavis
- Genomics England – Dr Maxine Mackintosh
Appendix C: engagement activities and acknowledgements

- Google Health – Dr Ivor Braden Horn, Anna Wojnarowska
- IBM iX – Flora MacLeod
- Microsoft Research – Dr Junaid Bajwa

Polygenic risk scores
- Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine – Dr Segun Fatumo
- Edmond and Lily Safra Center for Ethics, Harvard University – Dr Anna Lewis
- Genomics England – Dr Maxine Mackintosh
- Genomics PLC – Professor Sir Peter Donnelly
- IBM iX – Flora MacLeod
- Institute of Population Health, University of Liverpool – Professor David Taylor-Robinson
- NHS Race and Health Observatory – Dr Veline L’Esperance
- PHG Foundation – Dr Sowmiya Moorthie
- Wellcome Connecting Science – Sasha Henriques

Training and education
- Faculty of Medical Sciences, Newcastle University – Dr Jeffry Hogg
- Guy’s and St Thomas’ NHS Foundation Trust – Dr Haris Shuaib
- Health Education England – Dr Hatim Abdulhussein, Alan Davies
- IBM iX – Flora MacLeod
- Royal College of Emergency Medicine – Dr Emma Redfern

Devolved administrations

Northern Ireland
- Belfast Health and Social Care Trust – David Jennings
- Department of Health – David Wilson

Scotland
- Chief Medical Officer’s Policy Division, Scottish Government – Iain Robertson
- Incident Reporting and Investigation Centre – Innes Connor
- National Services Scotland – Kenny Rees
- Scottish Health Technologies Group – Dr Safia Qureshi

Wales
- Health and Social Services Group, Welsh Government – Natalie Harris
- NHS Wales Shared Services Partnership – Wyn Owens
Appendix C: engagement activities and acknowledgements

Support from the Department of Health and Social Care

Initiating and overseeing the early work:

- Sarah Lafond
- Chris Stirling

Support and guidance throughout:

- Dr Sara Felix
- David Lawson

Ongoing support and contribution throughout:

- Sia Thieba

Supporting delivery of commissioned work and procurement of an editor and designers:

- Daryl Mahabir
- Michael Murphy

Volunteering in late summer 2022, in addition to their own roles and responsibilities:

- Emily Casey
- Josh Crosley
- Joe Flannagan
- Bernice Huntley

Events and conferences

Members of the panel and the secretariat attended events, conferences and meetings across topics relevant to the review, including but not limited to:

- 7 and 8 July 2022 – NHS Race and Health Observatory, Health, Race and Racism International Conference
- 19 July 2022 – MedTech Trade Association Forum
- 19 July 2022 – Scottish CE Network Steering Group Monthly Meeting
- 1 November 2022 – US Food and Drug Administration, Center for Devices and Radiological Health, Medical Devices Advisory Committee, Anesthesiology Devices Panel
- 2 November 2022 – Federation of American Scientists, Bias in Pulse Oximetry Forum
- 3 November 2022 – National Institute for Health and Care Excellence, Positively Equal: How NICE is working to help reduce health inequalities
Appendix C: engagement activities and acknowledgements

- 15 December 2022 – Incidents and Alerts Safety Officer Network Meeting
- 9 March 2023 – Incident Reporting and Investigation Centre Spotlight Session
- 5 April 2023 – Medical Device Safety Officer Network Webex
- 18 April 2023 – Westminster Health Forum, Next steps for diagnostics and medical devices in England
- 25 April 2023 – MedTech – DACD Monthly Meeting

Technical Editing of the Report

- Richard Vize
Appendix D: call for evidence

Overview

The Independent Review ran an eight-week public consultation from 11 August to 8 October 2022, in the form of a call for evidence via an online survey hosted on the gov.uk website. It also accepted submissions via email.

Prior to its launch, the call for evidence was reviewed by stakeholders, including representatives of patient charities, industry representatives and the MHRA, and revised based on their feedback. Among other changes, questions were introduced on views and insights for those who may not have access to evidence.

Scope of the call for evidence

The call for evidence invited information concerning all medical devices across the entire device lifecycle, as well as ethnic and other unfair biases. It asked key open-ended questions on bias in medical devices, and respondents could upload attachments to support their responses. It asked not just for evidence, but also insights and views, to allow a broad range of individuals to contribute to the consultation.

The panel welcomed any data and evidence, including preliminary evidence and information on ongoing data collection and research or evaluation projects, regarding existing equity concerns or biases with respect to ethnicity or other socio-demographic characteristics, and any mitigating solutions. This could include:

- data and evidence related to ethnic and other unfair biases in relation to the development and use of medical devices
- examples of effective, successful or evidence-based approaches to mitigate these types of unfair biases and risks
- ideas for potential approaches to improving equity in the development and use of medical devices.

Audience

The call for evidence was open to the public and was shared with the media through the DHSC press office as well as directly through DHSC communication channels to relevant stakeholder groups.

Respondents could contribute as individuals sharing personal views and experiences, as individuals sharing professional views, or on behalf of organisations.
The panel welcomed contributions from all interested parties, but expected these topics to be of particular interest and relevance to:

- organisations representing diverse communities and patient groups, including charities
- community leaders
- academia, research, think tank and funding institutions
- clinicians and other healthcare professionals
- NHS and health improvement organisations
- industry, including medical device developers, manufacturers and innovators
- device regulators and standard-setters, including legal teams.

Patients and members of the public were invited to share their views and insights. If patients had concerns about the healthcare received they were provided with information about the relevant channels and support available through NHS England. Additionally, they were encouraged to report suspected side effects from medicines, vaccines, e-cigarettes, medical device incidents, defective or falsified (fake) products through to the MHRA’s Yellow Card reporting site.

**Results**

The consultation received 44 completed submissions via the online survey, and a further 7 submissions via email.

**Contributors**

Of the 44 online submissions, 9% of respondents were individuals sharing personal views and experiences, 43% were individuals sharing professional views, and 48% were submissions on behalf of an organisation.

The responses come from a wide range of organisations and sectors, including the device industry, healthcare providers, research, academia, standards and practice and a variety of medical specialities.

**Submissions**

At the start of the submission, contributors could mark which categories their submissions fall under (multiple answers were possible). Below is a list of how many submissions were self-classified as related to a specific medical device type (noting that some submissions referred to more than one type of device):

- Medical devices not enabled by AI – 29
- AI-enabled devices – 22
- Polygenic risk scores – 5
- None or I don't know – 2
- All other responses – 6
Below is the number of submissions classified by the respondents as falling into different categories of bias (noting that some submissions referred to more than one characteristic):

- Ethnicity – 32
- Gender and sex – 8
- Age – 5
- Disability – 4
- Socio-economic background/deprivation – 10
- None or I don’t know – 6
- All other responses – 4

There were few submissions from individual members of the public, and most of these were outside the scope of this review, covering issues surrounding access to and quality of medical care and devices, such as access to dental treatment and bias of healthcare professionals giving preferential treatment to white patients.

**Evidence included in submissions**

Of the online submissions, 17 said they had evidence relating to bias in design and development of medical devices, and 17 had evidence relating to bias in the use of medical devices. There was some degree of repetition between these answers and related attachments.

A total of 18 respondents said they knew of evidence-based solutions in the design and development of medical devices, and 14 of evidence-based solutions in the use of medical devices.

Most evidence provided drew on published research and academic papers.

**Key themes**

Key themes emerged, which are listed below. The findings for each were synthesised to inform the panel’s thinking as they developed their problem definition tables and recommendations. Multiple themes may have appeared in a single submission, and several submissions spoke to the same themes.

**Theme 1: issues of bias in the design and development of devices**

This included:

- unrepresentative or excluded populations in clinical trials, research, biobanks
- poorly worded regulations and standards leaving room for inadequate or insufficient design and development practices
- economic and practical challenges for companies to design and develop equitable medical devices (focus on the majority of users who will sustain business models)
• challenges in developing single all-encompassing AI models (arguments for targeted solutions that may not meet equity thresholds)
• poor standardisation and monitoring of devices.

Theme 2: issues of bias in the use of devices
This included:
• postcode lottery in access to medical devices (and care in general) – complex routes to inequality
• many socio-demographic and economic characteristics contributing to inequities in access and use of medical devices (including mental health, disabilities, language barriers, cultural factors)
• lack of instructions and/or calibration to different physical/biological parameters
• limited or poor quality of data collection within devices or while using them – challenges for monitoring and evaluation
• poor standards or regulations for risk control, warning labels
• off-label use or use of medical devices offered for free by NHS undergoing less scrutiny
• immature market and limited evidence/data available
• debate over effectiveness/equity leads to uncertainty and poorer quality.

Theme 3: solutions in the design and development of devices
This included:
• representation and diversity in datasets, user-groups, clinical trials etc. including demographic characteristics and lived experience of condition
• involvement of end users at development stage
• clarity in guidelines/regulation
• incentivising collection of demographic data by manufacturers
• importance of clean data (distinguishing between signal and noise in data)
• accessibility features such as braille, audio description, language options
• conduct research to identify under-served groups and bias/disparities to be addressed by manufacturers.

Theme 4: solutions in the use of devices
This included:
• using tools such as equality health impact assessments
• training/guidance on using devices among different groups – healthcare and patients
• considering ethnicity, children, the elderly, intersex and transgender people
• post-deployment monitoring/data
• recommendations of specific devices and tools
• incentivising collection of demographic data by manufacturers
• publication of evidence on how devices work among different groups
• clear guidance or ‘companion guide’ to reduce educational/literacy/digital access barriers to use.

How insights from the call for evidence were used

Responses were collated for the panel’s review. Additionally, the secretariat highlighted key themes from the written submissions and presented these to the panel to inform their thinking as they defined the key equity issues and developed draft recommendations.

Attached and referenced papers submitted were added to the Landscape Mapping document, which aimed to collect core materials on topics pertinent to the review. Suggestions and recommendations made by the respondents were extracted from the submissions and mapped against each of the solution types (such as data representativeness and fidelity, optimising the deployment), following the same process as the resources from the Landscape Mapping.
References

References


22 Obermeyer Z and others. Dissecting racial bias in an algorithm used to manage the health of populations. Science. October 2019.


35 Beard E and others. Ethnicity and socioeconomic status: missing in research means missing in clinical guidance. BJGP. June 2021.


References


51 FDA. Pulse oximeter accuracy and limitations: FDA safety communication. Updated 7 November 2022.

52 MHRA evidence to the Independent Review of Equity in Medical Devices. 2022.

53 Centre for Devices and Radiological Health. Medical devices advisory committee Anesthesiology devices panel. 1 November 2022.

54 MHRA evidence to the Independent Review of Equity in Medical Devices. 2022.

55 NHS Race & Health Observatory. Pulse oximetry and racial bias: Recommendations for national healthcare, regulatory and research bodies. March 2021.


57 Ehrenfeld J. Eliminating racial bias in medicine is an obligation we all share. American Medical Association. December 2022.

58 MHRA. UK approved bodies for medical devices. Updated 20 December 2022.


References


References


95 MHRA. Software and artificial intelligence (AI) as a medical device. April 2023.


123 Knight O and others. Effect of race, age, and axial length on optic nerve head parameters and retinal nerve fiber layer thickness measured by Cirrus HD-OCT. Archives of Ophthalmology. March 2012.


Department of Health and Social Care. UK to pilot world-leading approach to improve ethical adoption of AI in healthcare. 8 February 2022.


Alan Turing Institute. Health equity – how can we ensure that developments and applications of data science and AI improve everyone’s health? Accessed 18 May 2023.


Vasey B and others. Reporting guidelines for the early-stage clinical evaluation of the decision support systems driven by artificial intelligence: DECIDE-AI. BMJ. May 2022.

References


143 Cambridge University Health Partners. AI: Project InnerEye. 19 September 2016.


146 Hoverd E and others. Factors influencing decisions about whether to participate in health research by people of diverse ethnic and cultural backgrounds: a realist review. BMJ Open. May 2022.


150 UK Statistics Authority. Inclusive Data Taskforce recommendations report: leaving no one behind – how can we be more inclusive in our data? Updated 29 December 2022.


152 MHRA. Classification of general medical devices. Updated 26 June 2022.


155 MHRA. Software and AI as a medical device change programme – roadmap. Updated October 2022.

156 Schwartz R and others. Towards a standard for identifying and managing bias in artificial intelligence. NIST. March 2022.

References


159 Marr B. ChatGPT: what are hallucinations and why are they a problem for AI systems. Barnard Marr & Co. 22 March 2023.


172 Sud A and others. Realistic expectations are key to realising the benefits of polygenic scores. BMJ. 1 March 2023.


Sud A and others. Realistic expectations are key to realising the benefits of polygenic scores. BMJ. 1 March 2023.


Sud A and others. Realistic expectations are key to realising the benefits of polygenic scores. BMJ. 1 March 2023.

Sud A and others. Realistic expectations are key to realising the benefits of polygenic scores. BMJ. 1 March 2023.


